Skip Navigation

Patrick Y. Wen, MD


Neuro-oncology

Make an Appointment
Watch Video

Physician

  • Director, Center for Neuro-Oncology
  • Institute Physician
  • Professor of Neurology, Harvard Medical School

Centers/Programs

Clinical Interests

  • Brain and leptomeningeal metastases
  • Neurologic complications in cancer patients
  • Paraneoplastic syndromes
  • Primary brain and spinal cord tumors including gliomas, glioblastoma, primary CNS lymphoma, and ependymoma

Diseases Treated

  • Brain Metastasis
  • Brain Tumor (Primary)
  • Glioblastoma
  • Low-Grade Glioma
  • Lymphoma, Primary CNS
  • Meningioma

Contact Information

  • Appointments617-632-2166
  • Office Phone Number617-632-2166
  • Fax617-632-4773

Bio

Dr. Wen graduated from the Medical College of St. Bartholomew's Hospital, University of London, in 1981. He completed his internal medicine training at the University of London postgraduate hospitals and his neurology residency in the Harvard-Longwood Neurology Training Program. His research is focused on novel treatments of brain tumors, especially targeted molecular agents. His other clinical interests include neurologic complications of cancer.

Board Certification:

  • Neurology, 1989
  • Neuro-Oncology

Fellowship:

  • Harvard Medical School, Neurology

Residency:

  • Harvard-Longwood Neurology Training Program, Neurology
  • University of London, Internal Medicine

Medical School:

  • University of London

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Shields Warren 430 D
Boston MA, 02215
Get Directions

Research

Novel Therapies For Adult Brain Tumors

The primary goal of our multidisciplinary group of investigators is to find more effective treatments for patients with brain tumors. Our program is especially interested in the development of novel targeted molecular therapies. We currently have a large number of clinical trials of these agents in progress. Recently we also started trials of combinations of targeted molecular agents, which are likely to be more effective than treatment with single agents alone. As part of these trials, we are also genotyping the tumors and correlating them with response to treatment in the hope of identifying subgroups of patients who are particularly likely to benefit. In addition, we are conducting clinical trials evaluating novel inhibitors of angiogenesis, chemotherapy combinations, intratumoral agents delivered by convection, and tumor vaccines.

A second focus of our program is the development of novel therapies for meningiomas, brain metastases, and leptomeningeal metastases; clinical studies evaluating targeted molecular agents and novel chemotherapeutic agents against these cancers are under way. We also collaborate with colleagues in Pediatric Neuro-Oncology and the Department of Cancer Biology in a preclinical program directed at identifying novel targets for therapy and evaluating new agents for clinical trials.

In addition, our program has a strong interest in quality-of-life issues affecting patients with brain tumors, in particular, venous thromboembolic disease. We are currently studying the molecular basis of venous thromboembolism and evaluating the benefit of prophylactic anticoagulation. Furthermore, we are about to begin studies evaluating the role of prophylactic anticonvulsants in patients with malignant glioma who have not had seizures and medications such as methylphenidate for radiation-induced fatigue.

Dietrich J, Wen PY. Neurologic Complications of Chemotherapy. Schiff D, Kesari S, Wen PY, editors. Cancer Neurology in Clinical Practice. 2050.
View in: PubMed

Monje M, Wen PY. Neurological Complications of Oncology Therapy. Newton h, Jolesz F, editors. Handbook fo neuro-Oncology Neuro-Imaging. 2050.
View in: PubMed

Chi A, Norden A, Wen PY. Antiangiogenic Therapy for malignant Gliomas. Expert Rev in AntiCancer Therapy. 2050.
View in: PubMed

Wen PY. Cancer Neurology. Samuels MA, editor. Neurology for the Practicing Physician. 2050.
View in: PubMed

Drappatz J, Wen PY. Therapy for Peritumoral Edema in High Grade Gliomas. Rivista Medica. 2050.
View in: PubMed

Norden A, Wen PY. Targeted Molecular Therapies for Meningiomas. Nurosurg Focus. 2050.
View in: PubMed

Quant E, Wen PY. Neurologic complications of Bone Marrow Transplantation. Schiff D, Kesari S, Wen PY, editors. Cancer Neurology in Clinical Practice. 2050.
View in: PubMed

Savani A, Schiff D, Wen PY. Nervous System Metastases. Bradley W, daroff R, Fenichel G, Jankovic J, editors. Neurology in Clinical Practice. 2050.
View in: PubMed

Wen PY, Schiff D, editors. Brain Tumors in Adults. Neurologic Clinics. 2050.
View in: PubMed

Fitzsimmons A, Wen PY. Tumors of the Spinal Cord. Neurology: Basic and Clinical Neurosciences. 2050.
View in: PubMed

Schiff D, Wen PY. CNS toxicities from cancer therapy. Neurologic Clinics. 2050.
View in: PubMed

Chi A, Wen PY. Inhibiting Angiogenesis in Malignant Gliomas. Griswold W, Soffieti R, editors. handbook of Clinical Neurology: Neuro-Oncology. 2050.
View in: PubMed

Wen PY, Schiff D. Neurologic Complications of Prostate Cancer. Kantoff PW, Carroll P, D'Amico A, editors. Prostate Cancer. 2050.
View in: PubMed

Schiff D, Kesari S, Wen PY, editors. Cancer Neurology in Clinical Practice. 2050.
View in: PubMed

Monje M, Wen PY. Neurological Complications of Oncological therapy. Turner CD, Goldman S, editors. Late Effects of Treatment for Brain Tumors. 2050.
View in: PubMed

Cavaliere R, Wen PY, Schiff D. Novel Therapies in Brain Tumors. Neurol Clin. 2050.
View in: PubMed

Fitzsimmons A, Wen PY. Neurologic complications of chemotherpay. Newton H, Malkin M, editors. Neurologic complications of systemic cancer and antineoplastic therapy. 2050.
View in: PubMed

Wen PY. Transition: Message from the Editor-in-Chief. Neuro Oncol. 2017 Nov 29; 19(12):1567.
View in: PubMed

Grossmann P, Narayan V, Chang K, Rahman R, Abrey L, Reardon DA, Schwartz LH, Wen PY, Alexander BM, Huang R, Aerts HJWL. Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2017 Nov 29; 19(12):1688-1697.
View in: PubMed

Chang K, Bai HX, Zhou H, Su C, Bi WL, Agbodza E, Kavouridis VK, Senders JT, Boaro A, Beers AL, Zhang B, Capellini A, Liao W, Shen Q, Li X, Xiao B, Cryan J, Ramkissoon S, Ramkissoon L, Ligon KL, Wen PY, Bindra RS, Woo JH, Arnaout O, Gerstner E, Zhang PJ, Rosen B, Yang L, Huang RY, Kalpathy-Cramer J. Residual Convolutional Neural Network for Determination of IDH Status in Low- and High-grade Gliomas from MR Imaging. Clin Cancer Res. 2017 Nov 22.
View in: PubMed

Coroller TP, Bi WL, Huynh E, Abedalthagafi M, Aizer AA, Greenwald NF, Parmar C, Narayan V, Wu WW, Miranda de Moura S, Gupta S, Beroukhim R, Wen PY, Al-Mefty O, Dunn IF, Santagata S, Alexander BM, Huang RY, Aerts HJWL. Radiographic prediction of meningioma grade by semantic and radiomic features. PLoS One. 2017; 12(11):e0187908.
View in: PubMed

Chinnaiyan P, Won M, Wen PY, Rojiani AM, Werner-Wasik M, Shih HA, Ashby LS, Yu HM, Stieber VW, Malone SC, Fiveash JB, Mohile NA, Ahluwalia MS, Wendland MM, Stella PJ, Kee AY, Mehta MP. A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: Results of NRG Oncology RTOG 0913. Neuro Oncol. 2017 Nov 06.
View in: PubMed

Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, Fenstermaker RA, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Howard S, Junck L, Kaley T, Kumthekar P, Loeffler JS, Moots PL, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Ragsdale J, Rockhill J, Rogers L, Rusthoven C, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tsien C, Weiss S, Wen PY, Willmarth N, Bergman MA, Engh A. NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017 Nov; 15(11):1331-1345.
View in: PubMed

Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol. 2017 Oct 26; JCO2017736785.
View in: PubMed

Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski N, Taylor J, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD. Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma. Clin Cancer Res. 2017 Oct 26.
View in: PubMed

Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, Wen PY, Dunn IF, Bi WL, Weiss SE, Haas-Kogan DA, Alexander BM, Aizer AA. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017 Oct 19; 19(11):1511-1521.
View in: PubMed

Ellingson BM, Wen PY, Cloughesy TF. Evidence and Context of Use for Contrast Enhancement as a Surrogate of Disease Burden and Treatment Response in Malignant Glioma. Neuro Oncol. 2017 Oct 12.
View in: PubMed

Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, Abrey LE, Lieberman F, DeAngelis LM, Robins HI, Yung WKA, Chang S, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados M, Kuhn J, Cloughesy TF. Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. J Neurooncol. 2017 Oct 07.
View in: PubMed

Arvold ND, Shi DD, Aizer AA, Norden AD, Reardon DA, Lee EQ, Nayak L, Dunn IF, Golby AJ, Johnson MD, Claus EB, Chiocca EA, Ligon KL, Wen PY, Alexander BM. Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. J Neurooncol. 2017 Dec; 135(3):581-591.
View in: PubMed

Cloughesy TF, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Ping J, Holland J, Weitzman R, Wen PY. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. Neuro Oncol. 2017 Oct 03.
View in: PubMed

Sartor EA, Wen PY. Adjuvant treatments for ependymomas. J Neurosurg Sci. 2017 Sep 22.
View in: PubMed

Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY. Phase I/II Trial of Vorinostat Combined with Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma: Final Results of Alliance N0874/ABTC 02. Neuro Oncol. 2017 Aug 22.
View in: PubMed

Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, Cloughesy TF, Jiang T, Khasraw M, Li W, Mittman R, Poste GH, Wen PY, Yung WKA, Barker AD. Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. Clin Cancer Res. 2017 Aug 16.
View in: PubMed

Wen PY, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Cloughesy TF. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro Oncol. 2017 08 14.
View in: PubMed

Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, Claus EB, Lee EQ, Wen PY, Haas-Kogan DA, Alexander BM, Lin NU, Aizer AA. Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study. JAMA Oncol. 2017 Aug 01; 3(8):1069-1077.
View in: PubMed

Speranza MC, Passaro C, Ricklefs F, Kasai K, Klein SR, Nakashima H, Kaufmann JK, Ahmed AK, Nowicki MO, Obi P, Bronisz A, Aguilar-Cordova E, Aguilar LK, Guzik BW, Breakefield X, Weissleder R, Freeman GJ, Reardon DA, Wen P, Chiocca EA, Lawler SE. Preclinical investigation of gene-mediated cytotoxic immunotherapy and checkpoint blockade in glioblastoma. Neuro Oncol. 2017 Jul 24.
View in: PubMed

Tanguturi SK, Trippa L, Ramkissoon SH, Pelton K, Knoff D, Sandak D, Lindeman NI, Ligon AH, Beroukhim R, Parmigiani G, Wen PY, Ligon KL, Alexander BM. Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. Neuro Oncol. 2017 Jul 01; 19(7):908-917.
View in: PubMed

Ellingson BM, Gerstner ER, Smits M, Huang RY, Colen R, Abrey LE, Aftab DT, Schwab GM, Hessel C, Harris RJ, Chakhoyan A, Gahrmann R, Pope WB, Leu K, Raymond C, Woodworth DC, de Groot J, Wen PY, Batchelor TT, van den Bent MJ, Cloughesy TF. Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. Clin Cancer Res. 2017 Oct 01; 23(19):5745-5756.
View in: PubMed

Wen PY, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ. Response Assessment in Neuro-Oncology Clinical Trials. J Clin Oncol. 2017 Jul 20; 35(21):2439-2449.
View in: PubMed

Reardon DA, Wen PY, Wucherpfennig KW, Sampson JH. Immunomodulation for glioblastoma. Curr Opin Neurol. 2017 Jun; 30(3):361-369.
View in: PubMed

Arrillaga-Romany I, Chi AS, Allen JE, Oster W, Wen PY, Batchelor TT. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget. 2017 Oct 03; 8(45):79298-79304.
View in: PubMed

Arrillaga-Romany I, Chi AS, Allen JE, Oster W, Wen PY, Batchelor TT. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget. 2017 May 12.
View in: PubMed

Hundsberger T, Reardon DA, Wen PY. Angiogenesis inhibitors in tackling recurrent glioblastoma. Expert Rev Anticancer Ther. 2017 Jun; 17(6):507-515.
View in: PubMed

Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, Jaeckle K, Mehta M, Stupp R, Muzikansky A, Pentsova E, Cloughesy T, Iwamoto FM, Tonn JC, Vogelbaum MA, Wen PY, van den Bent MJ, Reardon DA. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro Oncol. 2017 05 01; 19(5):625-635.
View in: PubMed

van den Bent MJ, Weller M, Wen PY, Kros JM, Aldape K, Chang S. A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. Neuro Oncol. 2017 05 01; 19(5):614-624.
View in: PubMed

Chamberlain M, Junck L, Brandsma D, Soffietti R, Rudà R, Raizer J, Boogerd W, Taillibert S, Groves MD, Le Rhun E, Walker J, van den Bent M, Wen PY, Jaeckle KA. Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol. 2017 04 01; 19(4):484-492.
View in: PubMed

Ellingson BM, Wen PY, Cloughesy TF. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. Neurotherapeutics. 2017 Apr; 14(2):307-320.
View in: PubMed

Batchelor TT, Gerstner ER, Ye X, Desideri S, Duda DG, Peereboom D, Lesser GJ, Chowdhary S, Wen PY, Grossman S, Supko JG. Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-ß tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Neuro Oncol. 2017 04 01; 19(4):567-575.
View in: PubMed

Shankar GM, Abedalthagafi M, Vaubel RA, Merrill PH, Nayyar N, Gill CM, Brewster R, Bi WL, Agarwalla PK, Thorner AR, Reardon DA, Al-Mefty O, Wen PY, Alexander BM, van Hummelen P, Batchelor TT, Ligon KL, Ligon AH, Meyerson M, Dunn IF, Beroukhim R, Louis DN, Perry A, Carter SL, Giannini C, Curry WT, Cahill DP, Barker FG, Brastianos PK, Santagata S. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 04 01; 19(4):535-545.
View in: PubMed

Wen PY, Jiang T, Schiff D. How can we develop therapies for glioblastoma more efficiently? Randomized versus single-arm studies. Neuro Oncol. 2017 04 01; 19(4):459-460.
View in: PubMed

McFaline-Figueroa JR, Wen PY. The Viral Connection to Glioblastoma. Curr Infect Dis Rep. 2017 Feb; 19(2):5.
View in: PubMed

Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. J Neurooncol. 2017 Mar; 132(1):181-188.
View in: PubMed

Mehta M, Wen P, Nishikawa R, Reardon D, Peters K. Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. Crit Rev Oncol Hematol. 2017 Mar; 111:60-65.
View in: PubMed

Sun Y, Wen P, Yoon Y, Liu G, Steger M, Pfeiffer LN, West K, Snoke DW, Nelson KA. Bose-Einstein Condensation of Long-Lifetime Polaritons in Thermal Equilibrium. Phys Rev Lett. 2017 Jan 06; 118(1):016602.
View in: PubMed

Wen PY. Message from the Editor-in-Chief. Neuro Oncol. 2017 Jan; 19(1):1.
View in: PubMed

Ly KI, Wen PY. Clinical Relevance of Steroid Use in Neuro-Oncology. Curr Neurol Neurosci Rep. 2017 Jan; 17(1):5.
View in: PubMed

Kalpathy-Cramer J, Chandra V, Da X, Ou Y, Emblem KE, Muzikansky A, Cai X, Douw L, Evans JG, Dietrich J, Chi AS, Wen PY, Stufflebeam S, Rosen B, Duda DG, Jain RK, Batchelor TT, Gerstner ER. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. J Neurooncol. 2017 Feb; 131(3):603-610.
View in: PubMed

Miller JJ, Wen PY. Emerging targeted therapies for glioma. Expert Opin Emerg Drugs. 2016 Dec; 21(4):441-452.
View in: PubMed

Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M, Holmen SL, Jilaveanu LB, Lassman A, Moschos S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, Davies MA, Kluger HM. Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell Melanoma Res. 2016 Nov; 29(6):627-642.
View in: PubMed

Stevens MM, Maire CL, Chou N, Murakami MA, Knoff DS, Kikuchi Y, Kimmerling RJ, Liu H, Haidar S, Calistri NL, Cermak N, Olcum S, Cordero NA, Idbaih A, Wen PY, Weinstock DM, Ligon KL, Manalis SR. Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. Nat Biotechnol. 2016 Nov; 34(11):1161-1167.
View in: PubMed

Avila EK, Chamberlain M, Schiff D, Reijneveld JC, Armstrong TS, Ruda R, Wen PY, Weller M, Koekkoek JA, Mittal S, Arakawa Y, Choucair A, Gonzalez-Martinez J, MacDonald DR, Nishikawa R, Shah A, Vecht CJ, Warren P, van den Bent MJ, DeAngelis LM. Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. Neuro Oncol. 2017 Jan; 19(1):12-21.
View in: PubMed

Huang RY, Wen PY. Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints. Magn Reson Imaging Clin N Am. 2016 Nov; 24(4):705-718.
View in: PubMed

Ellingson BM, Harris RJ, Woodworth DC, Leu K, Zaw O, Mason WP, Sahebjam S, Abrey LE, Aftab DT, Schwab GM, Hessel C, Lai A, Nghiemphu PL, Pope WB, Wen PY, Cloughesy TF. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. Neuro Oncol. 2017 Jan; 19(1):89-98.
View in: PubMed

O'Neill AF, Qin L, Wen PY, de Groot JF, Van den Abbeele AD, Yap JT. Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma. J Neurooncol. 2016 Dec; 130(3):495-503.
View in: PubMed

Lee EQ, Wen PY. Corticosteroids for peritumoral edema: time to overcome our addiction? Neuro Oncol. 2016 Sep; 18(9):1191-2.
View in: PubMed

Arvold ND, Lee EQ, Mehta MP, Margolin K, Alexander BM, Lin NU, Anders CK, Soffietti R, Camidge DR, Vogelbaum MA, Dunn IF, Wen PY. Updates in the management of brain metastases. Neuro Oncol. 2016 Aug; 18(8):1043-65.
View in: PubMed

Hathout L, Patel V, Wen P. A 3-dimensional DTI MRI-based model of GBM growth and response to radiation therapy. Int J Oncol. 2016 Sep; 49(3):1081-7.
View in: PubMed

Eisele SC, Wen PY, Lee EQ. Assessment of Brain Tumor Response: RANO and Its Offspring. Curr Treat Options Oncol. 2016 Jul; 17(7):35.
View in: PubMed

Zhang B, Chang K, Ramkissoon S, Tanguturi S, Bi WL, Reardon DA, Ligon KL, Alexander BM, Wen PY, Huang RY. Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro Oncol. 2017 Jan; 19(1):109-117.
View in: PubMed

Miller MB, Bi WL, Ramkissoon LA, Kang YJ, Abedalthagafi M, Knoff DS, Agarwalla PK, Wen PY, Reardon DA, Alexander BM, Laws ER, Dunn IF, Beroukhim R, Ligon KL, Ramkissoon SH. MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma. Oncotarget. 2016 Jun 14; 7(24):37054-37063.
View in: PubMed

Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, Martinez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty KT, Wen PY, Shapiro GI. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. Cancer Discov. 2016 07; 6(7):740-53.
View in: PubMed

Chang K, Zhang B, Guo X, Zong M, Rahman R, Sanchez D, Winder N, Reardon DA, Zhao B, Wen PY, Huang RY. Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab. Neuro Oncol. 2016 Dec; 18(12):1680-1687.
View in: PubMed

Cabrera AR, Kirkpatrick JP, Fiveash JB, Shih HA, Koay EJ, Lutz S, Petit J, Chao ST, Brown PD, Vogelbaum M, Reardon DA, Chakravarti A, Wen PY, Chang E. Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol. 2016 Jul-Aug; 6(4):217-25.
View in: PubMed

Helfer JL, Wen PY, Blakeley J, Gilbert MR, Armstrong TS. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD). Neuro Oncol. 2016 Mar; 18 Suppl 2:ii26-ii36.
View in: PubMed

Wang GL, Liu Y, Qiu P, Zhou SF, Xu LF, Wen P, Wen JB, Xiao XZ. Cost-effectiveness of Lamivudine, Telbivudine, Adefovir Dipivoxil and Entecavir on decompensated hepatitis B virus-related cirrhosis. Eur Rev Med Pharmacol Sci. 2016 Mar; 20(5):866-72.
View in: PubMed

Lee EQ, Muzikansky A, Drappatz J, Kesari S, Wong ET, Fadul CE, Reardon DA, Norden AD, Nayak L, Rinne ML, Alexander BM, Arvold ND, Doherty L, Stefanik J, LaFrankie D, Ruland SF, Pulverenti J, Smith KH, Gaffey SC, Hammond S, Wen PY. A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. Neuro Oncol. 2016 06; 18(6):849-54.
View in: PubMed

Curry WT, Gorrepati R, Piesche M, Sasada T, Agarwalla P, Jones PS, Gerstner ER, Golby AJ, Batchelor TT, Wen PY, Mihm MC, Dranoff G. Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. Clin Cancer Res. 2016 Jun 15; 22(12):2885-96.
View in: PubMed

Abedalthagafi M, Bi WL, Aizer AA, Merrill PH, Brewster R, Agarwalla PK, Listewnik ML, Dias-Santagata D, Thorner AR, Van Hummelen P, Brastianos PK, Reardon DA, Wen PY, Al-Mefty O, Ramkissoon SH, Folkerth RD, Ligon KL, Ligon AH, Alexander BM, Dunn IF, Beroukhim R, Santagata S. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016 05; 18(5):649-55.
View in: PubMed

Diamandis P, Ferrer-Luna R, Huang RY, Folkerth RD, Ligon AH, Wen PY, Beroukhim R, Ligon KL, Ramkissoon SH. Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma. Diagn Pathol. 2016 Jan 27; 11:13.
View in: PubMed

Wen PY, Reardon DA. Neuro-oncology in 2015: Progress in glioma diagnosis, classification and treatment. Nat Rev Neurol. 2016 Feb; 12(2):69-70.
View in: PubMed

Wen PY. Message from the Editor-in-Chief. Neuro Oncol. 2016 Jan; 18(1):1.
View in: PubMed

Schiff D, Desjardins A, Cloughesy T, Mikkelsen T, Glantz M, Chamberlain MC, Reardon DA, Wen PY. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. Cancer. 2016 Feb 15; 122(4):582-7.
View in: PubMed

Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, Jones KL, Conway AS, Liao X, Zhou J, Wen PY, Van Den Abbeele AD, Hodi FS, Qin L, Kohl NE, Sharpe AH, Dranoff G, Freeman GJ. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res. 2016 Feb; 4(2):124-35.
View in: PubMed

Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015 Nov; 16(15):e534-42.
View in: PubMed

Levin VA, Tonge PJ, Gallo JM, Birtwistle MR, Dar AC, Iavarone A, Paddison PJ, Heffron TP, Elmquist WF, Lachowicz JE, Johnson TW, White FM, Sul J, Smith QR, Shen W, Sarkaria JN, Samala R, Wen PY, Berry DA, Petter RC. CNS Anticancer Drug Discovery and Development Conference White Paper. Neuro Oncol. 2015 Nov; 17 Suppl 6:vi1-26.
View in: PubMed

Huang RY, Rahman R, Ballman KV, Felten SJ, Anderson SK, Ellingson BM, Nayak L, Lee EQ, Abrey LE, Galanis E, Reardon DA, Pope WB, Cloughesy TF, Wen PY. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. Clin Cancer Res. 2016 Feb 01; 22(3):575-81.
View in: PubMed

Verreault M, Schmitt C, Goldwirt L, Pelton K, Haidar S, Levasseur C, Guehennec J, Knoff D, Labussière M, Marie Y, Ligon AH, Mokhtari K, Hoang-Xuan K, Sanson M, Alexander BM, Wen PY, Delattre JY, Ligon KL, Idbaih A. Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas. Clin Cancer Res. 2016 Mar 01; 22(5):1185-96.
View in: PubMed

Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 2016 Apr; 18(4):557-64.
View in: PubMed

Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Brown P, Butowski N, Chamberlain MC, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Holdhoff M, Junck L, Kaley T, Lawson R, Loeffler JS, Lovely MP, Moots PL, Mrugala MM, Newton HB, Parney I, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tran D, Tran N, Vrionis FD, Weiss S, Wen PY, McMillian N, Engh AM. Central Nervous System Cancers, Version 1.2015. J Natl Compr Canc Netw. 2015 Oct; 13(10):1191-202.
View in: PubMed

Chamberlain MC. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015 Sep 22; 85(12):1090.
View in: PubMed

Wen PY, Norden AD. Author response. Neurology. 2015 Sep 22; 85(12):1090.
View in: PubMed

Aizer AA, Abedalthagafi M, Bi WL, Horvath MC, Arvold ND, Al-Mefty O, Lee EQ, Nayak L, Rinne ML, Norden AD, Reardon DA, Wen PY, Ligon KL, Ligon AH, Beroukhim R, Dunn IF, Santagata S, Alexander BM. A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro Oncol. 2016 Feb; 18(2):269-74.
View in: PubMed

Nayak L, DeAngelis LM, Robins HI, Govindan R, Gadgeel S, Kelly K, Rigas JR, Peereboom DM, Rosenfeld SS, Muzikansky A, Zheng M, Urban P, Abrey LE, Omuro A, Wen PY. Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer. Cancer. 2015 Dec 01; 121(23):4165-72.
View in: PubMed

Aizer AA, Bi WL, Kandola MS, Lee EQ, Nayak L, Rinne ML, Norden AD, Beroukhim R, Reardon DA, Wen PY, Al-Mefty O, Arvold ND, Dunn IF, Alexander BM. Extent of resection and overall survival for patients with atypical and malignant meningioma. Cancer. 2015 Dec 15; 121(24):4376-81.
View in: PubMed

Gounder MM, Nayak L, Sahebjam S, Muzikansky A, Sanchez AJ, Desideri S, Ye X, Ivy SP, Nabors LB, Prados M, Grossman S, DeAngelis LM, Wen PY. Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors. J Clin Oncol. 2015 Oct 01; 33(28):3186-92.
View in: PubMed

Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, van den Bent MJ, Chang S, Yung WK, Cloughesy TF, Wen PY, Gilbert MR. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol. 2015 Sep; 17(9):1188-98.
View in: PubMed

Shankar GM, Francis JM, Rinne ML, Ramkissoon SH, Huang FW, Venteicher AS, Akama-Garren EH, Kang YJ, Lelic N, Kim JC, Brown LE, Charbonneau SK, Golby AJ, Sekhar Pedamallu C, Hoang MP, Sullivan RJ, Cherniack AD, Garraway LA, Stemmer-Rachamimov A, Reardon DA, Wen PY, Brastianos PK, Curry WT, Barker FG, Hahn WC, Nahed BV, Ligon KL, Louis DN, Cahill DP, Meyerson M. Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncol. 2015 Aug; 1(5):662-7.
View in: PubMed

Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, Nishikawa R, Rosenthal M, Wen PY, Stupp R, Reifenberger G. Glioma. Nat Rev Dis Primers. 2015 07 16; 1:15017.
View in: PubMed

Wen PY. Controversies in neuro-oncology: role of whole-brain radiation therapy in the treatment of newly diagnosed brain metastases. Neuro Oncol. 2015 Jul; 17(7):915.
View in: PubMed

Aizer AA, Du R, Wen PY, Arvold ND. Radiotherapy and death from cerebrovascular disease in patients with primary brain tumors. J Neurooncol. 2015 Sep; 124(2):291-7.
View in: PubMed

Rahman R, Catalano PJ, Reardon DA, Norden AD, Wen PY, Lee EQ, Nayak L, Beroukhim R, Dunn IF, Golby AJ, Johnson MD, Chiocca EA, Claus EB, Alexander BM, Arvold ND. Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation. J Neurooncol. 2015 Aug; 124(1):137-46.
View in: PubMed

Reardon DA, Ligon KL, Chiocca EA, Wen PY. One size should not fit all: advancing toward personalized glioblastoma therapy. Discov Med. 2015 Jun; 19(107):471-7.
View in: PubMed

Jafari-Khouzani K, Emblem KE, Kalpathy-Cramer J, Bjørnerud A, Vangel MG, Gerstner ER, Schmainda KM, Paynabar K, Wu O, Wen PY, Batchelor T, Rosen B, Stufflebeam SM. Repeatability of Cerebral Perfusion Using Dynamic Susceptibility Contrast MRI in Glioblastoma Patients. Transl Oncol. 2015 Jun; 8(3):137-46.
View in: PubMed

Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, Chang SM, Dancey J, de Vries EG, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wen PY. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015 Jun; 16(6):e270-8.
View in: PubMed

Wen PY, Omuro A, Ahluwalia MS, Fathallah-Shaykh HM, Mohile N, Lager JJ, Laird AD, Tang J, Jiang J, Egile C, Cloughesy TF. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. Neuro Oncol. 2015 Sep; 17(9):1275-83.
View in: PubMed

Gerstner ER, Ye X, Duda DG, Levine MA, Mikkelsen T, Kaley TJ, Olson JJ, Nabors BL, Ahluwalia MS, Wen PY, Jain RK, Batchelor TT, Grossman S. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1386-92.
View in: PubMed

Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol. 2015 Aug; 17(8):1051-63.
View in: PubMed

Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon KL, Wen PY. A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res. 2015 Aug 15; 21(16):3610-8.
View in: PubMed

Ding R, Feng L, He L, Chen Y, Wen P, Fu Z, Lin C, Yang S, Deng X, Zeng J, Sun G. Peroxynitrite decomposition catalyst prevents matrix metalloproteinase-9 activation and neurovascular injury after hemoglobin injection into the caudate nucleus of rats. Neuroscience. 2015 Jun 25; 297:182-93.
View in: PubMed

Arvold ND, Tanguturi SK, Aizer AA, Wen PY, Reardon DA, Lee EQ, Nayak L, Christianson LW, Horvath MC, Dunn IF, Golby AJ, Johnson MD, Claus EB, Chiocca EA, Ligon KL, Alexander BM. Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):384-9.
View in: PubMed

Rinne ML, Wen PY. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide. Oncology (Williston Park). 2015 Apr; 29(4):265, 275.
View in: PubMed

Neagu MR, Huang RY, Reardon DA, Wen PY. How treatment monitoring is influencing treatment decisions in glioblastomas. Curr Treat Options Neurol. 2015 Apr; 17(4):343.
View in: PubMed

Bruna J, Wen PY. Patient management problem. Continuum (Minneap Minn). 2015 Apr; 21(2 Neuro-oncology):535-40.
View in: PubMed

Bruna J, Wen PY. Patient management problem-preferred responses. Continuum (Minneap Minn). 2015 Apr; 21(2 Neuro-oncology):541-56.
View in: PubMed

Bergthold G, Bandopadhayay P, Hoshida Y, Ramkissoon S, Ramkissoon L, Rich B, Maire CL, Paolella BR, Schumacher SE, Tabak B, Ferrer-Luna R, Ozek M, Sav A, Santagata S, Wen PY, Goumnerova LC, Ligon AH, Stiles C, Segal R, Golub T, Grill J, Ligon KL, Chan JA, Kieran MW, Beroukhim R. Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro Oncol. 2015 Nov; 17(11):1486-96.
View in: PubMed

Ramkissoon SH, Bi WL, Schumacher SE, Ramkissoon LA, Haidar S, Knoff D, Dubuc A, Brown L, Burns M, Cryan JB, Abedalthagafi M, Kang YJ, Schultz N, Reardon DA, Lee EQ, Rinne ML, Norden AD, Nayak L, Ruland S, Doherty LM, LaFrankie DC, Horvath M, Aizer AA, Russo A, Arvold ND, Claus EB, Al-Mefty O, Johnson MD, Golby AJ, Dunn IF, Chiocca EA, Trippa L, Santagata S, Folkerth RD, Kantoff P, Rollins BJ, Lindeman NI, Wen PY, Ligon AH, Beroukhim R, Alexander BM, Ligon KL. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1344-55.
View in: PubMed

Huang RY, Neagu MR, Reardon DA, Wen PY. Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response. Front Neurol. 2015; 6:33.
View in: PubMed

Trippa L, Wen PY, Parmigiani G, Berry DA, Alexander BM. Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials. Neuro Oncol. 2015 Aug; 17(8):1106-13.
View in: PubMed

Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML, Chi AS, Batchelor TT, Hempfling K, McCluskey C, Smith KH, Gaffey SC, Wrigley B, Ligon KL, Raizer JJ, Wen PY. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol. 2015 Jun; 17(6):862-7.
View in: PubMed

Zhou L, Bondy SC, Jian L, Wen P, Yang F, Luo H, Li W, Zhou J. Tanshinone IIA attenuates the cerebral ischemic injury-induced increase in levels of GFAP and of caspases-3 and -8. Neuroscience. 2015 Mar 12; 288:105-11.
View in: PubMed

Reardon DA, Wen PY. Glioma in 2014: unravelling tumour heterogeneity-implications for therapy. Nat Rev Clin Oncol. 2015 Feb; 12(2):69-70.
View in: PubMed

Wen PY. Message from the Editor-in-Chief. Neuro Oncol. 2015 Jan; 17(1):1.
View in: PubMed

Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, Schiff D, Weber DC, Wen PY, Vogelbaum MA. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015 Jan; 122(1):4-23.
View in: PubMed

Jordan JT, Wen PY. Novel chemotherapeutic approaches in adult high-grade gliomas. Cancer Treat Res. 2015; 163:117-42.
View in: PubMed

Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET, Drappatz J, Lesser GJ, Haidar S, Beroukhim R, Lee EQ, Doherty L, Lafrankie D, Gaffey SC, Gerard M, Smith KH, McCluskey C, Phuphanich S, Wen PY. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015 Jan 20; 84(3):280-6.
View in: PubMed

Chheda MG, Wen PY, Hochberg FH, Chi AS, Drappatz J, Eichler AF, Yang D, Beroukhim R, Norden AD, Gerstner ER, Betensky RA, Batchelor TT. Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study. J Neurooncol. 2015 Feb; 121(3):627-34.
View in: PubMed

Taylor JW, Dietrich J, Gerstner ER, Norden AD, Rinne ML, Cahill DP, Stemmer-Rachamimov A, Wen PY, Betensky RA, Giorgio DH, Snodgrass K, Randall AE, Batchelor TT, Chi AS. Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J Neurooncol. 2015 Feb; 121(3):557-63.
View in: PubMed

Gilbert MR, Armstrong TS, Pope WB, van den Bent MJ, Wen PY. Facing the future of brain tumor clinical research. Clin Cancer Res. 2014 Nov 15; 20(22):5591-600.
View in: PubMed

Nabors LB, Portnow J, Ammirati M, Brem H, Brown P, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, Moots PL, Mrugala MM, Newton HB, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tran D, Tran N, Vrionis FD, Wen PY, McMillian NR, Ho M. Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2014 Nov; 12(11):1517-23.
View in: PubMed

Schiff D, Lee EQ, Nayak L, Norden AD, Reardon DA, Wen PY. Medical management of brain tumors and the sequelae of treatment. Neuro Oncol. 2015 Apr; 17(4):488-504.
View in: PubMed

Barone A, Sengupta R, Warrington NM, Smith E, Wen PY, Brekken RA, Romagnoli B, Douglas G, Chevalier E, Bauer MP, Dembowsky K, Piwnica-Worms D, Rubin JB. Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma. Oncotarget. 2014 Oct 30; 5(20):9811-22.
View in: PubMed

Norden AD, Schiff D, Ahluwalia MS, Lesser GJ, Nayak L, Lee EQ, Rinne ML, Muzikansky A, Dietrich J, Purow B, Doherty LM, LaFrankie DC, Pulverenti JR, Rifenburg JA, Ruland SF, Smith KH, Gaffey SC, McCluskey C, Ligon KL, Reardon DA, Wen PY. Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. J Neurooncol. 2015 Jan; 121(2):297-302.
View in: PubMed

Reardon DA, Wen PY, Mellinghoff IK. Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro Oncol. 2014 Oct; 16 Suppl 8:viii7-13.
View in: PubMed

Wen PY, Cloughesy TF, Ellingson BM, Reardon DA, Fine HA, Abrey L, Ballman K, Bendszuz M, Buckner J, Chang SM, Prados MD, Pope WB, Gregory Sorensen A, van den Bent M, Yung WK. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol. 2014 Oct; 16 Suppl 7:vii36-47.
View in: PubMed

Ellingson BM, Wen PY, van den Bent MJ, Cloughesy TF. Pros and cons of current brain tumor imaging. Neuro Oncol. 2014 Oct; 16 Suppl 7:vii2-11.
View in: PubMed

Cryan JB, Haidar S, Ramkissoon LA, Bi WL, Knoff DS, Schultz N, Abedalthagafi M, Brown L, Wen PY, Reardon DA, Dunn IF, Folkerth RD, Santagata S, Lindeman NI, Ligon AH, Beroukhim R, Hornick JL, Alexander BM, Ligon KL, Ramkissoon SH. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget. 2014 Sep 30; 5(18):8083-92.
View in: PubMed

Field KM, Jordan JT, Wen PY, Rosenthal MA, Reardon DA. Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies. Cancer. 2015 Apr 01; 121(7):997-1007.
View in: PubMed

Reardon DA, Freeman G, Wu C, Chiocca EA, Wucherpfennig KW, Wen PY, Fritsch EF, Curry WT, Sampson JH, Dranoff G. Immunotherapy advances for glioblastoma. Neuro Oncol. 2014 Nov; 16(11):1441-58.
View in: PubMed

Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, Wen PY. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro Oncol. 2015 Feb; 17(2):180-8.
View in: PubMed

Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, Norden A, Drappatz J, Lee EQ, Purow B, Plotkin SR, Batchelor T, Abrey LE, Omuro A. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015 Jan; 17(1):116-21.
View in: PubMed

Lee EQ, Ruland S, LeBoeuf NR, Wen PY, Santagata S. Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy. J Clin Oncol. 2016 Apr 01; 34(10):e87-9.
View in: PubMed

Wen PY. Point/counterpoint: is there a role for radiotherapy in the treatment of primary CNS lymphoma? Neuro Oncol. 2014 Aug; 16(8):1032.
View in: PubMed

Panageas KS, Reiner AS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Lassman AB. Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro Oncol. 2014 Nov; 16(11):1541-6.
View in: PubMed

Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen B, Loeffler JS, Wen PY, Sorensen AG, Jain RK. Increased perfusion due to vascular normalization improves oxygenation and survival in glioblastoma patients treated with cediranib with or without chemoradiation. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii12.
View in: PubMed

Wen PY, Wen PY, Yung WK, Mellinghoff IK, Ramkissoon S, Alexander B, Rinne M, Colman H, Omuro AM, DeAngelis LM, Gilbert MR, DeGroot J, Cloughesy TF, Lee EQ, Nayak L, Chi AS, Batchelor T, Chang SM, Prados MD, Reardon DA, Ligon KL. Phase ii trial of the phosphatidyinositol-3 kinase (pi3k) inhibitor buparlisib (bkm120) in recurrent glioblastoma conducted by the ivy foundation early phase clinical trials consortium. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii47.
View in: PubMed

Rahman R, Hempfling K, Norden AD, Reardon DA, Nayak L, Rinne ML, Beroukhim R, Doherty L, Ruland S, Rai A, Rifenburg J, LaFrankie D, Alexander BM, Huang RY, Wen PY, Lee EQ. Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. Neuro Oncol. 2014 Nov; 16(11):1523-9.
View in: PubMed

Liu W, Ye H, Tang B, Song Z, Sun Z, Wen P, Yang J. Profile of interdialytic ambulatory blood pressure in a cohort of Chinese patients. J Hum Hypertens. 2014 Nov; 28(11):677-83.
View in: PubMed

Aizer AA, Arvold ND, Catalano P, Claus EB, Golby AJ, Johnson MD, Al-Mefty O, Wen PY, Reardon DA, Lee EQ, Nayak L, Rinne ML, Beroukhim R, Weiss SE, Ramkissoon SH, Abedalthagafi M, Santagata S, Dunn IF, Alexander BM. Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro Oncol. 2014 Nov; 16(11):1547-53.
View in: PubMed

Chamberlain M, Soffietti R, Raizer J, Rudà R, Brandsma D, Boogerd W, Taillibert S, Groves MD, Le Rhun E, Junck L, van den Bent M, Wen PY, Jaeckle KA. Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro Oncol. 2014 Sep; 16(9):1176-85.
View in: PubMed

Rahman R, Hamdan A, Zweifler R, Jiang H, Norden AD, Reardon DA, Mukundan S, Wen PY, Huang RY. Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab. J Neurooncol. 2014 Aug; 119(1):149-58.
View in: PubMed

Akgoz A, Rahman R, You H, Qu J, Hamdan A, Seethamraju RT, Wen PY, Young GS. Spin-echo echo-planar perfusion prior to chemoradiation is a strong independent predictor of progression-free and overall survival in newly diagnosed glioblastoma. J Neurooncol. 2014 Aug; 119(1):111-9.
View in: PubMed

Olson JJ, Nayak L, Ormond DR, Wen PY, Kalkanis SN. The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2014 Jul; 118(3):501-55.
View in: PubMed

Olson JJ, Nayak L, Ormond DR, Wen PY, Kalkanis SN, Ryken TC. The role of targeted therapies in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2014 Jul; 118(3):557-99.
View in: PubMed

Wen PY, Junck L. Bevacizumab for glioblastoma: what can we learn from patterns of progression? Neurology. 2014 May 13; 82(19):1670-1.
View in: PubMed

Reardon DA, Wen PY. Targeted therapies: Further delineating bevacizumab's response spectrum. Nat Rev Clin Oncol. 2014 May; 11(5):243-4.
View in: PubMed

Lee JW, Norden AD, Ligon KL, Golby AJ, Beroukhim R, Quackenbush J, Wells W, Oelschlager K, Maetzold D, Wen PY. Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: a gene expression imaging study. Epilepsy Res. 2014 Jul; 108(5):843-52.
View in: PubMed

Wen PY. Controversies in neuro-oncology: does valganciclovir have a role in the treatment of high-grade gliomas? Neuro Oncol. 2014 Mar; 16(3):329.
View in: PubMed

Wang TS, Lei W, Cui W, Wen P, Guo HF, Ding SG, Yang YP, Xu YQ, Lv SW, Zhu YL. A meta-analysis of bevacizumab combined with chemotherapy in the treatment of ovarian cancer. Indian J Cancer. 2014 Mar; 51 Suppl 3:e95-8.
View in: PubMed

Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, Rogers L, Schiff D, Vogelbaum M, Weber D, Wen P. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol. 2014 Jun; 16(6):829-40.
View in: PubMed

Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol. 2014 Apr; 16(4):567-78.
View in: PubMed

Wen PY. New editorial team for neuro-oncology. Neuro Oncol. 2014 Jan; 16(1):1.
View in: PubMed

Arrillaga-Romany I, Reardon DA, Wen PY. Current status of antiangiogenic therapies for glioblastomas. Expert Opin Investig Drugs. 2014 Feb; 23(2):199-210.
View in: PubMed

Pinho MC, Polaskova P, Kalpathy-Cramer J, Jennings D, Emblem KE, Jain RK, Rosen BR, Wen PY, Sorensen AG, Batchelor TT, Gerstner ER. Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation. Oncologist. 2014 Jan; 19(1):75-81.
View in: PubMed

Huse JT, Wallace M, Aldape KD, Berger MS, Bettegowda C, Brat DJ, Cahill DP, Cloughesy T, Haas-Kogan DA, Marra M, Miller CR, Nelson SJ, Salama SR, Soffietti R, Wen PY, Yip S, Yen K, Costello JF, Chang S. Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. Neuro Oncol. 2014 Jan; 16(2):173-8.
View in: PubMed

Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen BR, Loeffler JS, Wen PY, Sorensen AG, Jain RK. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):19059-64.
View in: PubMed

Lin NU, Wefel JS, Lee EQ, Schiff D, van den Bent MJ, Soffietti R, Suh JH, Vogelbaum MA, Mehta MP, Dancey J, Linskey ME, Camidge DR, Aoyama H, Brown PD, Chang SM, Kalkanis SN, Barani IJ, Baumert BG, Gaspar LE, Hodi FS, Macdonald DR, Wen PY. Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol. 2013 Sep; 14(10):e407-16.
View in: PubMed

Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Camidge DR, Chang SM, Dancey J, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Lamborn KR, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Wen PY. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol. 2013 Sep; 14(10):e396-406.
View in: PubMed

Nabors LB, Ammirati M, Bierman PJ, Brem H, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, Maor MH, Moots PL, Morrison T, Mrugala MM, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK, Tran D, Tran N, Vrionis FD, Wen PY, McMillian N, Ho M. Central nervous system cancers. J Natl Compr Canc Netw. 2013 Sep 01; 11(9):1114-51.
View in: PubMed

Chen C, Huang R, MacLean A, Muzikansky A, Mukundan S, Wen PY, Norden AD. Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival. J Neurooncol. 2013 Nov; 115(2):267-76.
View in: PubMed

Emblem KE, Mouridsen K, Bjornerud A, Farrar CT, Jennings D, Borra RJ, Wen PY, Ivy P, Batchelor TT, Rosen BR, Jain RK, Sorensen AG. Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med. 2013 Sep; 19(9):1178-83.
View in: PubMed

Cankovic M, Nikiforova MN, Snuderl M, Adesina AM, Lindeman N, Wen PY, Lee EQ. The role of MGMT testing in clinical practice: a report of the association for molecular pathology. J Mol Diagn. 2013 Sep; 15(5):539-55.
View in: PubMed

Alexander BM, Wen PY, Trippa L, Reardon DA, Yung WK, Parmigiani G, Berry DA. Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2. Neuro Oncol. 2013 Aug; 15(8):972-8.
View in: PubMed

Zhang JP, Lee EQ, Nayak L, Doherty L, Kesari S, Muzikansky A, Norden AD, Chen H, Wen PY, Drappatz J. Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma. J Neurooncol. 2013 Oct; 115(1):71-7.
View in: PubMed

Huang RY, Rahman R, Hamdan A, Kane C, Chen C, Norden AD, Reardon DA, Mukundun S, Wen PY. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab. Cancer. 2013 Oct 01; 119(19):3479-88.
View in: PubMed

Wen P, Wang X, Wang J, Zhang B, Qiu G, Fan Y, Xu Y, Tang H, Sun X, Peng Z. A simple technique for a new working heterotopic heart transplantation model in rats. Transplant Proc. 2013 Jul-Aug; 45(6):2522-6.
View in: PubMed

Reardon DA, Wucherpfennig KW, Freeman G, Wu CJ, Chiocca EA, Wen PY, Curry WT, Mitchell DA, Fecci PE, Sampson JH, Dranoff G. An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines. 2013 Jun; 12(6):597-615.
View in: PubMed

Lee EQ, Nayak L, Wen PY, Reardon DA. Treatment options in newly diagnosed glioblastoma. Curr Treat Options Neurol. 2013 Jun; 15(3):281-8.
View in: PubMed

Chinnaiyan P, Won M, Wen PY, Rojiani AM, Wendland M, Dipetrillo TA, Corn BW, Mehta MP. RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2013 Aug 01; 86(5):880-4.
View in: PubMed

Wen P, Nelson KA. Selective enhancements in 2D Fourier transform optical spectroscopy with tailored pulse shapes. J Phys Chem A. 2013 Jul 25; 117(29):6380-7.
View in: PubMed

Rinne ML, Lee EQ, Nayak L, Norden AD, Beroukhim R, Wen PY, Reardon DA. Update on bevacizumab and other angiogenesis inhibitors for brain cancer. Expert Opin Emerg Drugs. 2013 Jun; 18(2):137-53.
View in: PubMed

Alexander BM, Ligon KL, Wen PY. Enhancing radiation therapy for patients with glioblastoma. Expert Rev Anticancer Ther. 2013 May; 13(5):569-81.
View in: PubMed

Warren KE, Poussaint TY, Vezina G, Hargrave D, Packer RJ, Goldman S, Wen PY, Pollack IF, Zurakowski D, Kun LE, Prados MD, Rutkowski S, Kieran MW. Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group. Pediatr Blood Cancer. 2013 Sep; 60(9):1397-401.
View in: PubMed

Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor TT, Zhu JJ, Beroukhim R, Muzikansky A, Doherty L, Lafrankie D, Smith K, Tafoya V, Lis R, Stack EC, Rosenfeld MR, Wen PY. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol. 2013 Jul; 15(7):930-5.
View in: PubMed

Alexander BM, Lee EQ, Reardon DA, Wen PY. Current and future directions for Phase II trials in high-grade glioma. Expert Rev Neurother. 2013 Apr; 13(4):369-87.
View in: PubMed

Villano JL, Wen PY, Lee EQ, Nayak L, Reardon DA, Rosenfeld MR. PCV for anaplastic oligodendrogliomas: back to the future or a step backwards? A point/counterpoint discussion. J Neurooncol. 2013 May; 113(1):143-7.
View in: PubMed

Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM. Reply to B. Freidlin et al. J Clin Oncol. 2013 Mar 01; 31(7):970-1.
View in: PubMed

Saria MG, Corle C, Hu J, Rudnick JD, Phuphanich S, Mrugala MM, Crew LK, Bota DA, Dan Fu B, Kim RY, Brown T, Feely H, Brechlin J, Brown BD, Drappatz J, Wen PY, Chen CC, Carter B, Lee JW, Kesari S. Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article. J Neurosurg. 2013 Jun; 118(6):1183-7.
View in: PubMed

Wang X, Zielinski MC, Misawa R, Wen P, Wang TY, Wang CZ, Witkowski P, Hara M. Quantitative analysis of pancreatic polypeptide cell distribution in the human pancreas. PLoS One. 2013; 8(1):e55501.
View in: PubMed

Reardon DA, Groves MD, Wen PY, Nabors L, Mikkelsen T, Rosenfeld S, Raizer J, Barriuso J, McLendon RE, Suttle AB, Ma B, Curtis CM, Dar MM, de Bono J. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin Cancer Res. 2013 Feb 15; 19(4):900-8.
View in: PubMed

Shonka N, Piao Y, Gilbert M, Yung A, Chang S, DeAngelis LM, Lassman AB, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Heymach J, de Groot J. Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. Target Oncol. 2013 Jun; 8(2):117-25.
View in: PubMed

Drappatz J, Brenner A, Wong ET, Eichler A, Schiff D, Groves MD, Mikkelsen T, Rosenfeld S, Sarantopoulos J, Meyers CA, Fielding RM, Elian K, Wang X, Lawrence B, Shing M, Kelsey S, Castaigne JP, Wen PY. Phase I study of GRN1005 in recurrent malignant glioma. Clin Cancer Res. 2013 Mar 15; 19(6):1567-76.
View in: PubMed

Hu J, Wen PY, Abrey LE, Fadul CE, Drappatz J, Salem N, Supko JG, Hochberg F. A phase II trial of oral gimatecan for recurrent glioblastoma. J Neurooncol. 2013 Feb; 111(3):347-53.
View in: PubMed

Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados MD, Cloughesy TF, Gilbert MR, Wen PY. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol. 2012 Dec; 14(12):1511-8.
View in: PubMed

Zhou SQ, Wen P, Fang L, Jiang L, Xiong M, Zhang FF, Yang JW. The association between RhEPO and FN expression in glomerular mesangial cells. Panminerva Med. 2012 Sep; 54(3):205-9.
View in: PubMed

Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn KR, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Xu J, Desideri S, Ye X, Ames MM, Espinoza-Delgado I, Prados MD, Wen PY. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res. 2012 Nov 01; 18(21):6032-9.
View in: PubMed

Chi AS, Batchelor TT, Dias-Santagata D, Borger D, Stiles CD, Wang DL, Curry WT, Wen PY, Ligon KL, Ellisen L, Louis DN, Iafrate AJ. Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol. 2012 Oct; 110(1):89-98.
View in: PubMed

Nayak L, Abrey LE, Drappatz J, Gilbert MR, Reardon DA, Wen PY, Prados M, Deangelis LM, Omuro A. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leuk Lymphoma. 2013 Jan; 54(1):58-61.
View in: PubMed

Craig JM, Vena N, Ramkissoon S, Idbaih A, Fouse SD, Ozek M, Sav A, Hill DA, Margraf LR, Eberhart CG, Kieran MW, Norden AD, Wen PY, Loda M, Santagata S, Ligon KL, Ligon AH. DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PLoS One. 2012; 7(6):e38881.
View in: PubMed

Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, Deangelis LM, Jhanwar SC, Rosenblum MK, Lassman AB. Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro Oncol. 2012 Jun; 14(6):761-7.
View in: PubMed

Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol. 2012 Sep 10; 30(26):3258-63.
View in: PubMed

Wen PY, Lee EQ, Reardon DA, Ligon KL, Alfred Yung WK. Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol. 2012 Jul; 14(7):819-29.
View in: PubMed

Galanis E, Wu W, Cloughesy T, Lamborn K, Mann B, Wen PY, Reardon DA, Wick W, Macdonald D, Armstrong TS, Weller M, Vogelbaum M, Colman H, Sargent DJ, van den Bent MJ, Gilbert M, Chang S. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol. 2012 May; 13(5):e196-204.
View in: PubMed

Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, Butowski N, Groves MD, Kesari S, Freedman SJ, Blackman S, Watters J, Loboda A, Podtelezhnikov A, Lunceford J, Chen C, Giannotti M, Hing J, Beckman R, Lorusso P. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol. 2012 Jul 01; 30(19):2307-13.
View in: PubMed

Rinne ML, Lee EQ, Wen PY. Central nervous system complications of cancer therapy. J Support Oncol. 2012 Jul-Aug; 10(4):133-41.
View in: PubMed

Chamberlain MC, Cloughsey T, Reardon DA, Wen PY. A novel treatment for glioblastoma: integrin inhibition. Expert Rev Neurother. 2012 Apr; 12(4):421-35.
View in: PubMed

Lee EQ, Arrillaga-Romany IC, Wen PY. Neurologic complications of cancer drug therapies. Continuum (Minneap Minn). 2012 Apr; 18(2):355-65.
View in: PubMed

Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, DeAngelis LM, Yong WH, Kuhn JG, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012 May; 2(5):458-71.
View in: PubMed

Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, Yung WK, Young GS, Vredenburgh J, Barboriak D, Abrey LE, Mikkelsen T, Jain R, Paleologos NA, Rn PL, Prados M, Goldin J, Wen PY, Cloughesy T. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol. 2012 Jul; 108(3):491-8.
View in: PubMed

Armstrong TS, Wen PY, Gilbert MR, Schiff D. Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro Oncol. 2012 Oct; 14(10):1203-14.
View in: PubMed

Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012 Feb; 14(1):48-54.
View in: PubMed

Das RR, Artsy E, Hurwitz S, Wen PY, Black P, Golby A, Dworetzky B, Lee JW. Outcomes after discontinuation of antiepileptic drugs after surgery in patients with low grade brain tumors and meningiomas. J Neurooncol. 2012 May; 107(3):565-70.
View in: PubMed

Chi AS, Wen PY. Inhibiting angiogenesis in malignant gliomas. Handb Clin Neurol. 2012; 104:279-308.
View in: PubMed

Vogelbaum MA, Jost S, Aghi MK, Heimberger AB, Sampson JH, Wen PY, Macdonald DR, Van den Bent MJ, Chang SM. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery. 2012 Jan; 70(1):234-43; discussion 243-4.
View in: PubMed

Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo M, Merlini G, Voorhees P, Chng WJ, Mazumder A, Usmani S, Einsele H, Comenzo R, Orlowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos M, Lonial S, Jagannath S, Bladé J, Miguel JS, Morgan G, Anderson KC, Durie BG, Sonneveld P. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012 Apr; 26(4):595-608.
View in: PubMed

Blakeley JO, Evans DG, Adler J, Brackmann D, Chen R, Ferner RE, Hanemann CO, Harris G, Huson SM, Jacob A, Kalamarides M, Karajannis MA, Korf BR, Mautner VF, McClatchey AI, Miao H, Plotkin SR, Slattery W, Stemmer-Rachamimov AO, Welling DB, Wen PY, Widemann B, Hunter-Schaedle K, Giovannini M. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A. 2012 Jan; 158A(1):24-41.
View in: PubMed

Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, Wang M, Wen PY, Ivy P, Batchelor TT, Jain RK. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 2012 Jan 15; 72(2):402-7.
View in: PubMed

Alexander BM, Pinnell N, Wen PY, D'Andrea A. Targeting DNA repair and the cell cycle in glioblastoma. J Neurooncol. 2012 May; 107(3):463-77.
View in: PubMed

Reardon DA, Wen PY, Alfred Yung WK, Berk L, Narasimhan N, Turner CD, Clackson T, Rivera VM, Vogelbaum MA. Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial. Cancer Chemother Pharmacol. 2012 Apr; 69(4):849-60.
View in: PubMed

Drappatz J, Lee EQ, Hammond S, Grimm SA, Norden AD, Beroukhim R, Gerard M, Schiff D, Chi AS, Batchelor TT, Doherty LM, Ciampa AS, Lafrankie DC, Ruland S, Snodgrass SM, Raizer JJ, Wen PY. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J Neurooncol. 2012 Mar; 107(1):133-8.
View in: PubMed

Kesselheim JC, Norden AD, Wen PY, Joffe S. Discontinuing bevacizumab in patients with glioblastoma: an ethical analysis. Oncologist. 2011; 16(10):1435-9.
View in: PubMed

Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol. 2012 Jan; 106(2):409-15.
View in: PubMed

Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, Dejesus J, Lisiero DD, Huang TT, Prins RM, Wen PY, Robins HI, Prados MD, Deangelis LM, Mellinghoff IK, Mehta MP, James CD, Chakravarti A, Cloughesy TF, Tontonoz P, Mischel PS. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov. 2011 Oct; 1(5):442-56.
View in: PubMed

Wen PY, Schiff D. Valproic acid as the AED of choice for patients with glioblastoma? The jury is out. Neurology. 2011 Sep 20; 77(12):1114-5.
View in: PubMed

Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, Prados MD. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol. 2011 Oct; 13(10):1118-24.
View in: PubMed

Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, Chabner BA, Flaherty K, de Groot JF, Gilbert MR, Galanis E, Chang SM, Schwartz GK, Peereboom D, Mehta MP, Yung WK, Grossman SA, Prados MD, DeAngelis LM. It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol. 2011 Aug 20; 29(24):3211-3.
View in: PubMed

Gilbert MR, Kuhn J, Lamborn KR, Lieberman F, Wen PY, Mehta M, Cloughesy T, Lassman AB, Deangelis LM, Chang S, Prados M. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol. 2012 Jan; 106(1):147-53.
View in: PubMed

Norden AD, Bartolomeo J, Tanaka S, Drappatz J, Ciampa AS, Doherty LM, Lafrankie DC, Ruland S, Quant EC, Beroukhim R, Wen PY. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J Neurooncol. 2012 Jan; 106(1):121-5.
View in: PubMed

Bhatt RS, Zurita AJ, O'Neill A, Norden-Zfoni A, Zhang L, Wu HK, Wen PY, George D, Sukhatme VP, Atkins MB, Heymach JV. Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma. Br J Cancer. 2011 Jun 28; 105(1):112-7.
View in: PubMed

Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Panageas KS. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol. 2011 Jun; 13(6):649-59.
View in: PubMed

de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WK, Prados M, Wen PY, Heymach JV. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res. 2011 Jul 15; 17(14):4872-81.
View in: PubMed

de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, Prados MD, Wen PY. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2011 Jul 01; 29(19):2689-95.
View in: PubMed

Quant EC, Batchelor T, Lassman AB, Schiff D, Kaley TJ, Wong E, Mikkelsen T, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, Sceppa C, Gerard M, Hallisey SD, Bochacki CA, Smith KH, Muzikansky A, Wen PY. Preliminary results from a multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma (GBM). J Clin Oncol. 2011 May 20; 29(15_suppl):2069.
View in: PubMed

Nayak L, Abrey LE, Drappatz J, Gilbert MR, Reardon DA, Lamborn K, Wen PY, Prados M, DeAngelis LM, Omuro AM. Multicenter phase II trial of temozolomide (TMZ) and rituximab (RIT) for recurrent primary CNS lymphoma (PCNSL): North American Brain Tumor Consortium (NABTC) study 05-01. J Clin Oncol. 2011 May 20; 29(15_suppl):2039.
View in: PubMed

Drappatz J, Raizer JJ, Schiff D, Chi AS, Batchelor T, Snodgrass SM, Quant EC, Norden AD, Beroukhim R, Grimm SA, Doherty LM, Ciampa AS, LaFrankie DC, Ruland S, Gerard M, Hammond S, Wen PY. A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG). J Clin Oncol. 2011 May 20; 29(15_suppl):2050.
View in: PubMed

Norden AD, Hammond S, Drappatz J, Phuphanich S, Reardon DA, Wong E, Plotkin SR, Lesser GJ, Raizer JJ, Batchelor T, Quant EC, Beroukhim R, Kaley TJ, Muzikansky A, Ciampa AS, Doherty LM, Smith KH, Gerard M, Sceppa C, Wen PY. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. J Clin Oncol. 2011 May 20; 29(15_suppl):2040.
View in: PubMed

De Groot JF, Cloughesy T, Lieberman FS, Chang SM, Omuro AM, Drappatz J, Batchelor T, DeAngelis LM, Gilbert MR, Yung WK, Fisher JD, Ye X, Lamborn K, Chen AP, Grossman SA, Prados M, Wen PY. Phase I study of aflibercept (VEGF Trap) and temozolomide in newly diagnosed, high-grade glioma. J Clin Oncol. 2011 May 20; 29(15_suppl):2043.
View in: PubMed

Hammond S, Norden AD, Lesser GJ, Drappatz J, Fadul CE, Batchelor T, Quant EC, Beroukhim R, Muzikansky A, Ciampa AS, Doherty LM, LaFrankie DC, Ruland S, Bochacki CA, Griffin K, Gerard M, Sceppa C, Rosenfeld MR, Wen PY. Phase II study of dose-intense temozolomide in recurrent glioblastoma. J Clin Oncol. 2011 May 20; 29(15_suppl):2038.
View in: PubMed

Wen PY, Puduvalli VK, Kuhn JG, Reid JM, Lamborn K, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Desideri S, Ye X, Ames MM, Espinoza-Delgado IJ, Grossman SA, Prados M. Phase I study of vorinostat in combination with temozolomide in patients with malignant gliomas. J Clin Oncol. 2011 May 20; 29(15_suppl):2032.
View in: PubMed

Wefel JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Jun; 13(6):660-8.
View in: PubMed

Ahluwalia MS, Wen PY. Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions. Expert Rev Anticancer Ther. 2011 May; 11(5):653-6.
View in: PubMed

van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, Armstrong T, Choucair A, Waldman AD, Gorlia T, Chamberlain M, Baumert BG, Vogelbaum MA, Macdonald DR, Reardon DA, Wen PY, Chang SM, Jacobs AH. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011 Jun; 12(6):583-93.
View in: PubMed

Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Junck L, Linette GP, Loeffler JS, Maor MH, Michael M, Moots PL, Morrison T, Mrugala M, Nabors LB, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK, Vrionis FD, Wen PY. Central nervous system cancers. J Natl Compr Canc Netw. 2011 Apr; 9(4):352-400.
View in: PubMed

Cao Y, Zou SM, Zhang KT, Lu N, Liu Y, Feng L, Wen P, Han NJ, Lin DM. Genetic alterations in pulmonary epithelioid hemangioendothelioma and epithelioid angiosarcoma. Histol Histopathol. 2011 04; 26(4):491-6.
View in: PubMed

Iwamoto FM, Lamborn KR, Kuhn JG, Wen PY, Yung WK, Gilbert MR, Chang SM, Lieberman FS, Prados MD, Fine HA. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol. 2011 May; 13(5):509-16.
View in: PubMed

Mellinghoff IK, Lassman AB, Wen PY. Signal transduction inhibitors and antiangiogenic therapies for malignant glioma. Glia. 2011 Aug; 59(8):1205-12.
View in: PubMed

Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol. 2011 Mar; 13(3):353-61.
View in: PubMed

Wen PY, Schiff D, Cloughesy TF, Raizer JJ, Laterra J, Smitt M, Wolf M, Oliner KS, Anderson A, Zhu M, Loh E, Reardon DA. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol. 2011 Apr; 13(4):437-46.
View in: PubMed

Quant EC, Wen PY. Response assessment in neuro-oncology. Curr Oncol Rep. 2011 Feb; 13(1):50-6.
View in: PubMed

Chaponis D, Barnes JW, Dellagatta JL, Kesari S, Fast E, Sauvageot C, Panagrahy D, Greene ER, Ramakrishna N, Wen PY, Kung AL, Stiles C, Kieran MW. Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. J Neurooncol. 2011 Aug; 104(1):179-89.
View in: PubMed

di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte ET, Sorensen AG, Batchelor TT, Jain RK. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res. 2011 Jan 01; 71(1):19-28.
View in: PubMed

Lu-Emerson C, Norden AD, Drappatz J, Quant EC, Beroukhim R, Ciampa AS, Doherty LM, Lafrankie DC, Ruland S, Wen PY. Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. J Neurooncol. 2011 Aug; 104(1):287-91.
View in: PubMed

Vredenburgh JJ, Cloughesy T, Samant M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Das A, Friedman HS. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist. 2010; 15(12):1329-34.
View in: PubMed

Young GS, Macklin EA, Setayesh K, Lawson JD, Wen PY, Norden AD, Drappatz J, Kesari S. Longitudinal MRI evidence for decreased survival among periventricular glioblastoma. J Neurooncol. 2011 Aug; 104(1):261-9.
View in: PubMed

Mou X, Kesari S, Wen PY, Huang X. Crude drugs as anticancer agents. Int J Clin Exp Med. 2011; 4(1):17-25.
View in: PubMed

Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Jan; 13(1):143-51.
View in: PubMed

Nghiemphu PL, Wen PY, Lamborn KR, Drappatz J, Robins HI, Fink K, Malkin MG, Lieberman FS, DeAngelis LM, Torres-Trejo A, Chang SM, Abrey L, Fine HA, Demopoulos A, Lassman AB, Kesari S, Mehta MP, Prados MD, Cloughesy TF. A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):1422-7.
View in: PubMed

Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, Duda DG, Wen PY, Jain RK, Batchelor TT. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol. 2011 Jun; 103(2):325-32.
View in: PubMed

Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD. Medical therapies for meningiomas. J Neurooncol. 2010 Sep; 99(3):365-78.
View in: PubMed

Wen PY. American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section. Expert Rev Anticancer Ther. 2010 Sep; 10(9):1367-9.
View in: PubMed

Quant EC, Wen PY. Novel medical therapeutics in glioblastomas, including targeted molecular therapies, current and future clinical trials. Neuroimaging Clin N Am. 2010 Aug; 20(3):425-48.
View in: PubMed

Quant EC, Drappatz J, Wen PY, Norden AD. Recurrent high-grade glioma. Curr Treat Options Neurol. 2010 Jul; 12(4):321-33.
View in: PubMed

Norden AD, Drappatz J, Wen PY, Claus EB. Survival among patients with primary central nervous system lymphoma, 1973-2004. J Neurooncol. 2011 Feb; 101(3):487-93.
View in: PubMed

Dou J, Wu Y, Wang J, Zhao F, Chu L, Liu C, Wen P, Hu W, Hu K, He XF, Gu N. Eliciting protective immune responses against murine myeloma challenge in lymphopenia mice through adoptive transfer of tumor antigen-specific lymphocytes and immunization of tumor vaccine secreting mIL-21. Cancer Gene Ther. 2010 Oct; 17(10):675-83.
View in: PubMed

Passarin MG, Wen PY, Vattemi E, Buffone E, Ghimenton C, Bontempini L, Ottaviani S, Musso AM, Pedersini R. Intravascular lymphomatosis and intracerebral haemorrhage. Neurol Sci. 2010 Dec; 31(6):793-7.
View in: PubMed

Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010 Jun 10; 28(17):2817-23.
View in: PubMed

Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 2010 May-Jun; 60(3):166-93.
View in: PubMed

Wen PY. Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role? J Clin Oncol. 2010 Apr 20; 28(12):1977-9.
View in: PubMed

Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010 Apr 10; 28(11):1963-72.
View in: PubMed

Lee JW, Wen PY, Hurwitz S, Black P, Kesari S, Drappatz J, Golby AJ, Wells WM, Warfield SK, Kikinis R, Bromfield EB. Morphological characteristics of brain tumors causing seizures. Arch Neurol. 2010 Mar; 67(3):336-42.
View in: PubMed

Scott BJ, Quant EC, McNamara MB, Ryg PA, Batchelor TT, Wen PY. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro Oncol. 2010 Jun; 12(6):603-7.
View in: PubMed

Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, Schiff D, Batchelor TT, Ligon KL, Young G, Muzikansky A, Weiss SE, Wen PY. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2010 Sep 01; 78(1):85-90.
View in: PubMed

Gerstner ER, Chen PJ, Wen PY, Jain RK, Batchelor TT, Sorensen G. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol. 2010 May; 12(5):466-72.
View in: PubMed

Wen PY. Cerebral spinal fluid abnormalities in patients with paraneoplastic syndromes of the nervous system. J Neurol Neurosurg Psychiatry. 2010 Jan; 81(1):3.
View in: PubMed

Wen PY, Norden AD, Drappatz J, Quant E. Response assessment challenges in clinical trials of gliomas. Curr Oncol Rep. 2010 Jan; 12(1):68-75.
View in: PubMed

Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, Zhu S, Kofman AA, Bensinger SJ, Yong WH, Vinters HV, Horvath S, Watson AD, Kuhn JG, Robins HI, Mehta MP, Wen PY, DeAngelis LM, Prados MD, Mellinghoff IK, Cloughesy TF, Mischel PS. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal. 2009 Dec 15; 2(101):ra82.
View in: PubMed

Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol. 2010 Jan; 12(1):95-103.
View in: PubMed

Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KD, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol. 2010 Jan; 12(1):87-94.
View in: PubMed

Wen PY. New therapies for recurrent glioblastomas. F1000 Med Rep. 2009 Dec 09; 1.
View in: PubMed

Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol. 2009 Dec; 11(6):853-60.
View in: PubMed

Wen PY, Brandes AA. Treatment of recurrent high-grade gliomas. Curr Opin Neurol. 2009 Dec; 22(6):657-64.
View in: PubMed

Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol. 2009 Nov; 5(11):610-20.
View in: PubMed

Snuderl M, Eichler AF, Ligon KL, Vu QU, Silver M, Betensky RA, Ligon AH, Wen PY, Louis DN, Iafrate AJ. Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res. 2009 Oct 15; 15(20):6430-7.
View in: PubMed

Wu X, Liu Y, Li X, Wen P, Zhang Y, Long Y, Wang X, Guo Y, Xing F, Gao J. Preparation of aligned porous gelatin scaffolds by unidirectional freeze-drying method. Acta Biomater. 2010 Mar; 6(3):1167-77.
View in: PubMed

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 01; 27(28):4733-40.
View in: PubMed

Schiff D, Wen PY, van den Bent MJ. Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol. 2009 Oct; 6(10):596-603.
View in: PubMed

Saad AG, Alyea EP, Wen PY, Degirolami U, Kesari S. Graft-versus-host disease of the CNS after allogeneic bone marrow transplantation. J Clin Oncol. 2009 Oct 20; 27(30):e147-9.
View in: PubMed

Dou J, Li Y, Zhao F, Hu W, Wen P, Tang Q, Chu L, Wang Y, Cao M, Jiang C, Gu N. Identification of tumor stem-like cells in a mouse myeloma cell line. Cell Mol Biol (Noisy-le-grand). 2009 Aug 05; 55 Suppl:OL1151-60.
View in: PubMed

Samuel DP, Wen PY, Kieran MW. Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. Expert Opin Investig Drugs. 2009 Jul; 18(7):973-83.
View in: PubMed

Chi AS, Norden AD, Wen PY. Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics. 2009 Jul; 6(3):513-26.
View in: PubMed

Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010 Jan; 96(2):211-7.
View in: PubMed

Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009 Jul 01; 69(13):5296-300.
View in: PubMed

Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009 Jul 20; 27(21):3518-25.
View in: PubMed

Lu J, Xue LY, Lu N, Zou SM, Liu XY, Wen P. Superficial primary small cell carcinoma of the esophagus: clinicopathological and immunohistochemical analysis of 15 cases. Dis Esophagus. 2010 Feb; 23(2):153-9.
View in: PubMed

Prados M, Gilbert M, Kuhn J, Lamborn K, Cloughesy T, Lieberman F, Puduvalli V, Robins HI, Lassman A, Wen PY. Phase I/II study of sorefenib and erlotinib for patients with recurrent glioblastoma (GBM) (NABTC 05-02). J Clin Oncol. 2009 May 20; 27(15_suppl):2005.
View in: PubMed

DePrimo S, Wu B, Huang S, Bautista R, Cancilla B, Vysotskaia V, De Groot J, Prados M, Buller R, Wen P. Correlative tumor molecular profiling and plasma biomarker analysis in a phase II study of XL184 in patients with progressive or recurrent glioblastoma multiforme (GBM). J Clin Oncol. 2009 May 20; 27(15_suppl):2049.
View in: PubMed

Chi AS, Gerstner ER, Eichler AF, Chea HK, Drappatz J, Wen PY, Ivy SP, Loeffler JS, Sorensen AG, Jain RK, Batchelor TT. Phase Ib study of cediranib in combination with daily temozolomide and radiation in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):e13010.
View in: PubMed

Batchelor T, Eichler AF, Plotkin SR, Drappatz J, Wen P, Sorensen AG, Gerstner E. Phase I trial of vatalanib (PTK787) in combination with standard radiation and temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):2035.
View in: PubMed

Chang SM, Kuhn J, Lamborn K, Cloughesy T, Robins I, Lieberman F, Yung A, Dancey J, Prados M, Wen P. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04-02). J Clin Oncol. 2009 May 20; 27(15_suppl):2004.
View in: PubMed

Norden AD, Raizer JJ, Lamborn KR, Abrey LE, Chang SM, Gilbert MR, Cloughesy TF, Prados MD, Lieberman F, Wen P. Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomas. J Clin Oncol. 2009 May 20; 27(15_suppl):2062.
View in: PubMed

Wen PY, Cloughesy T, Kuhn J, Lamborn K, Abrey LE, Lieberman F, Robins HI, Wright J, Prados MD, Gilbert M. Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02). J Clin Oncol. 2009 May 20; 27(15_suppl):2006.
View in: PubMed

De Groot JF, Prados M, Urquhart T, Robertson S, Yaron Y, Sorensen AG, Norton A, Batchelor T, Drappatz J, Wen P. A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse. J Clin Oncol. 2009 May 20; 27(15_suppl):2047.
View in: PubMed

Kuhn JG, Gilbert M, Wen P, Cloughesy T, Cooper J, Puduvalli V, DeAngelis L, Lieberman F, Lamborn K, Prados M. Interaction between sorafenib and erlotinib. J Clin Oncol. 2009 May 20; 27(15_suppl):2500.
View in: PubMed

Hu J, Wen PY, Abrey LE, Fadul C, Drappatz J, Salem N, Amato A, Carminati P, Supko J, Hochberg F. Phase II trial of oral gimatecan in adults with recurrent glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):2009.
View in: PubMed

Sorensen AG, Jenning D, Wang M, Andronesi O, Chen P, Prados M, Wen P, Jackson E, Cha S, deGroot J. Use of neurovascular imaging in GBM patients (pts) to quantify early physiologic changes after treatment with XL184, an inhibitor of multiple receptor tyrosine kinases: Results from a phase II study. J Clin Oncol. 2009 May 20; 27(15_suppl):2048.
View in: PubMed

Drappatz J, Norden AD, Wong ET, Lassman AB, Doherty L, LaFrankie D, Gerard M, Phan P, Schiff D, Wen PY. Phase I study of vandetanib with radiation therapy and temozolomide for newly diagnosed glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):2031.
View in: PubMed

Piao Y, Heymach JV, Bekele B, Camphausen K, Wen PY, Liu J, Yung WK, De Groot J. Circulating cytokine and angiogenic factors as predictive biomarkers of glioblastoma response to aflibercept (VEGF Trap). J Clin Oncol. 2009 May 20; 27(15_suppl):2029.
View in: PubMed

van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol. 2009 Jun 20; 27(18):2905-8.
View in: PubMed

Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep. 2009 May; 9(3):231-40.
View in: PubMed

Drappatz J, Norden AD, Wen PY. Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Rev Neurother. 2009 Apr; 9(4):519-34.
View in: PubMed

Quant EC, Norden AD, Drappatz J, Muzikansky A, Doherty L, Lafrankie D, Ciampa A, Kesari S, Wen PY. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol. 2009 Oct; 11(5):550-5.
View in: PubMed

Gerstner ER, McNamara MB, Norden AD, Lafrankie D, Wen PY. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol. 2009 Aug; 94(1):97-101.
View in: PubMed

Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Boral AL, Esseltine DL, Wen PY, Amato AA, Anderson KC, San Miguel J. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009 Mar; 144(6):895-903.
View in: PubMed

Monje M, Wen PY. Neurological complications in adults. Cancer Treat Res. 2009; 150:113-32.
View in: PubMed

Wen PY. New developments in targeted molecular therapies for glioblastoma. Expert Rev Anticancer Ther. 2009 Jan; 9(1):7-10.
View in: PubMed

Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muzikansky A, Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G, Ramakrishna N, Black PM, Wen PY. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res. 2009 Jan 01; 15(1):330-7.
View in: PubMed

Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 2008 Dec; 7(12):1152-60.
View in: PubMed

Dietrich J, Norden AD, Wen PY. Emerging antiangiogenic treatments for gliomas - efficacy and safety issues. Curr Opin Neurol. 2008 Dec; 21(6):736-44.
View in: PubMed

Norden AD, Drappatz J, Muzikansky A, David K, Gerard M, McNamara MB, Phan P, Ross A, Kesari S, Wen PY. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol. 2009 Apr; 92(2):149-55.
View in: PubMed

Norden AD, Drappatz J, Wen PY. Antiangiogenic therapy in malignant gliomas. Curr Opin Oncol. 2008 Nov; 20(6):652-61.
View in: PubMed

Bracht LK, Wen P, Meyerhardt JA, Kulke MH, Hornick JL, Redston M, LaFrankie DC, Black PM, Kesari S, Norden A, Drappatz J. DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor. J Clin Oncol. 2008 Oct 10; 26(29):4843-4.
View in: PubMed

Haining WN, Davies J, Kanzler H, Drury L, Brenn T, Evans J, Angelosanto J, Rivoli S, Russell K, George S, Sims P, Neuberg D, Li X, Kutok J, Morgan J, Wen P, Demetri G, Coffman RL, Nadler LM. CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin Cancer Res. 2008 Sep 01; 14(17):5626-34.
View in: PubMed

Norden AD, Drappatz J, Ciampa AS, Doherty L, LaFrankie DC, Kesari S, Wen PY. Colon perforation during antiangiogenic therapy for malignant glioma. Neuro Oncol. 2009 Feb; 11(1):92-5.
View in: PubMed

Fadul CE, Wen PY, Kim L, Olson JJ. Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme. J Neurooncol. 2008 Sep; 89(3):339-57.
View in: PubMed

Sorensen AG, Batchelor TT, Wen PY, Zhang WT, Jain RK. Response criteria for glioma. Nat Clin Pract Oncol. 2008 Nov; 5(11):634-44.
View in: PubMed

Sauvageot CM, Weatherbee JL, Kesari S, Winters SE, Barnes J, Dellagatta J, Ramakrishna NR, Stiles CD, Kung AL, Kieran MW, Wen PY. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol. 2009 Apr; 11(2):109-21.
View in: PubMed

Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008 Jul 31; 359(5):492-507.
View in: PubMed

Kesari S, Drappatz J, Akar S, Vergilio JA, Wen PY, Soiffer RJ, Stone RM, Deangelo DJ. Recurrent acute promyelocytic leukemia presenting as a sacral nerve root mass. J Clin Oncol. 2008 Jul 01; 26(19):3279-81.
View in: PubMed

Gerstner ER, Abrey LE, Schiff D, Ferreri AJ, Lister A, Montoto S, Tsang R, Thiel E, Graus F, Behringer D, Illerhaus G, Weaver S, Wen P, Voloschin A, Harris NL, Batchelor TT. CNS Hodgkin lymphoma. Blood. 2008 Sep 01; 112(5):1658-61.
View in: PubMed

Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Wen PY, Fine HA, Mehta MP, DeAngelis LM, Lieberman FS, Cloughesy TF, Robins HI, Abrey LE, Prados MD. Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro Oncol. 2008 Aug; 10(4):631-42.
View in: PubMed

Kesari S, Kim RS, Markos V, Drappatz J, Wen PY, Pruitt AA. Prognostic factors in adult brainstem gliomas: a multicenter, retrospective analysis of 101 cases. J Neurooncol. 2008 Jun; 88(2):175-83.
View in: PubMed

Drappatz J, Wong ET, Schiff D, Kesari S, Batchelor TT, Doherty L, Lafrankie DC, Ramakrishna N, Weiss S, Smith ST, Ciampa A, Zimmerman J, Ostrowsky L, David K, Norden A, Barron L, Sceppa C, Black PM, Wen PY. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):222-7.
View in: PubMed

Reardon DA, Cloughsey TF, Raizer JJ, Laterra J, Schiff D, Yang X, Loh E, Wen PY. Phase II study of AMG 102, a fully human neutralizing antibody against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme. J Clin Oncol. 2008 May 20; 26(15_suppl):2051.
View in: PubMed

Cloughesy TF, Prados MD, Wen PY, Mikkelsen T, Abrey LE, Schiff D, Yung WK, Maoxia Z, Dimery I, Friedman HS. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol. 2008 May 20; 26(15_suppl):2010b.
View in: PubMed

Kesari S, Schiff D, Henson JW, Muzikansky A, Gigas DC, Doherty L, Batchelor TT, Longtine JA, Ligon KL, Weaver S, Laforme A, Ramakrishna N, Black PM, Drappatz J, Ciampa A, Folkman J, Kieran M, Wen PY. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol. 2008 Jun; 10(3):300-8.
View in: PubMed

Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther. 2008 Apr; 8(4):541-53.
View in: PubMed

Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008 Apr; 10(2):162-70.
View in: PubMed

Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008 Mar 04; 70(10):779-87.
View in: PubMed

Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D, Conrad C, Fink KL, Robins HI, Mehta M, DeAngelis L, Raizer J, Hess K, Lamborn KR, Dancey J, Prados MD. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res. 2007 Dec 15; 13(24):7401-6.
View in: PubMed

Loghin ME, Prados MD, Wen P, Junck L, Lieberman F, Fine H, Fink KL, Metha M, Kuhn J, Lamborn K, Chang SM, Cloughesy T, DeAngelis LM, Robins IH, Aldape KD, Yung WK. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. Clin Cancer Res. 2007 Dec 01; 13(23):7133-8.
View in: PubMed

Chi A, Norden AD, Wen PY. Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev Anticancer Ther. 2007 Nov; 7(11):1537-60.
View in: PubMed

Drappatz J, Schiff D, Kesari S, Norden AD, Wen PY. Medical management of brain tumor patients. Neurol Clin. 2007 Nov; 25(4):1035-71, ix.
View in: PubMed

Cavaliere R, Wen PY, Schiff D. Novel therapies for malignant gliomas. Neurol Clin. 2007 Nov; 25(4):1141-71, x.
View in: PubMed

Voloschin AD, Betensky R, Wen PY, Hochberg F, Batchelor T. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol. 2008 Jan; 86(2):211-5.
View in: PubMed

Prados MD, Yung WK, Wen PY, Junck L, Cloughesy T, Fink K, Chang S, Robins HI, Dancey J, Kuhn J. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemother Pharmacol. 2008 May; 61(6):1059-67.
View in: PubMed

Wen PY, DeAngelis LM. Chemotherapy for low-grade gliomas: emerging consensus on its benefits. Neurology. 2007 May 22; 68(21):1762-3.
View in: PubMed

Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O'Neill A, Drappatz J, Chen-Plotkin AS, Ramakrishna N, Weiss SE, Levy B, Bradshaw J, Kracher J, Laforme A, Black PM, Folkman J, Kieran M, Wen PY. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol. 2007 Jul; 9(3):354-63.
View in: PubMed

Ngo TT, Peng T, Liang XJ, Akeju O, Pastorino S, Zhang W, Kotliarov Y, Zenklusen JC, Fine HA, Maric D, Wen PY, De Girolami U, Black PM, Wu WW, Shen RF, Jeffries NO, Kang DW, Park JK. The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. J Natl Cancer Inst. 2007 Apr 18; 99(8):639-52.
View in: PubMed

Chi AS, Wen PY. Inhibiting kinases in malignant gliomas. Expert Opin Ther Targets. 2007 Apr; 11(4):473-96.
View in: PubMed

Chheda MG, Drappatz J, Greenberger NJ, Kesari S, Weiss SE, Gigas DC, Doherty LM, Wen PY. Hepatitis B reactivation during glioblastoma treatment with temozolomide: a cautionary note. Neurology. 2007 Mar 20; 68(12):955-6.
View in: PubMed

Monje ML, Ramakrishna NR, Young G, Drappatz J, Doherty LM, Wen PY, Kesari S. Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide. J Neurooncol. 2007 Sep; 84(2):179-83.
View in: PubMed

Narin O, Drappatz J, Doherty LM, Wen PY, Kesari S. Cerebrospinal fluid spread of anaplastic glioma. J Clin Oncol. 2007 Feb 10; 25(5):596-7.
View in: PubMed

Robins HI, Chang SM, Kuhn J, Lamborn K, Cloughesy T, Gilbert MR, Yung WKA, Dancey J, Prados MD, Wen PY. Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (NABTC 04-02). Proc ASCO. 2007.
View in: PubMed

Wen PY, Puduvalli V, Kuhn J, Cloughesy T, Yung WKA, Chang SM, Lamborn K, Robins HI, Ames M, Zweibel J, Prados MD. Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with temozolomide (TMX) in patients with malignant gliomas (NABTC 04-03). Proc ASCO. 2007.
View in: PubMed

Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007 Jan; 11(1):83-95.
View in: PubMed

Batchelor TT, Soresen AG, Ancukiewicz M, Duda DG, Louis DN, Plotkin SR, Ivy P, Wen PY, Loeffler J, Jain R. A phase II trial of AZD2171 (cediranib) an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastomas. Proc ASCO. 2007; Abstr 2001.
View in: PubMed

Wen PY, Drappatz J. Volumetric MRI- Key to finding better treatments for plexiform neurofibromas? [commentary]. Neurology. 2007; 68:627.
View in: PubMed

Norden AD, Drappatz J, Wen PY. Targeted drug therapy for meningiomas. Neurosurg Focus. 2007; 23(4):E12.
View in: PubMed

Selected Topics in Cancer Neurology. 2007.
View in: PubMed

Drappatz J. Won ET, Schiff D, Gigas D, Doherty L, Kesari S, Batchelor TT, Weiss S, Ramakrishna N, Smith ST. David K, Ostrowsky L, Zimmerman J, Black PM, Wen PY. Pilot safety study of lenalidomdie and radiation therapy in patients with newly diagnosed glioblastoma. American Academy of Neurology 59th Annual Meeting. 2007.
View in: PubMed

Abrey LE, Wen PYm, Govindan R, Reimers HJ, Rigas JR, Robins HI, de Bedout S, O'Connell C, Li X, Johri A. Activity of patupilone for the treatment of recurrent or progressive brain metastases in patients with non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II study. Proc ASCO. 2007.
View in: PubMed

Reardon DA, Groves M, Wen PY, Nabor L, Mikkelsen T, Rosenfel S, Harris D, Demarini D, Suttle B, Arumugham T, Hodge J, Lager J. A Phase II Trial Of Lapatinib And Pazopanib For Patients With Recurrent Glioblastoma Multiforme (GBM). Society For Neuro-Oncology 12th Annual Meeting. 2007.
View in: PubMed

Schiff D, Wen P. Central nervous system toxicity from cancer therapies. Hematol Oncol Clin North Am. 2006 Dec; 20(6):1377-98.
View in: PubMed

Maher EA, Brennan C, Wen PY, Durso L, Ligon KL, Richardson A, Khatry D, Feng B, Sinha R, Louis DN, Quackenbush J, Black PM, Chin L, DePinho RA. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res. 2006 Dec 01; 66(23):11502-13.
View in: PubMed

Knappenberger KL, Lerch EB, Wen P, Leone SR. Coherent polyatomic dynamics studied by femtosecond time-resolved photoelectron spectroscopy: dissociation of vibrationally excited CS2 in the 6s and 4d Rydberg states. J Chem Phys. 2006 Nov 07; 125(17):174314.
View in: PubMed

Norden AD, Wen PY. Glioma therapy in adults. Neurologist. 2006 Nov; 12(6):279-92.
View in: PubMed

Oaklander AL, Richardson PG, Briemberg H, Wen P, Anderson KC, Chan-Khan AA, Schlossmana RL, Munshi NC, Heffner LT< Hassoun H, Avigan DE, Amato A. Multiple myeloma ployneuropath before and after initial chemotherapy with single-agent bortezomib. 131st Annual Meeting of the American Neurological Association. 2006.
View in: PubMed

Wen PY, Drappatz J. Novel therapies for meningiomas. Expert Rev Neurother. 2006 Oct; 6(10):1447-64.
View in: PubMed

Drappatz J, Wen PY. Chemotherapy and targeted molecular therapies for brain metastases. Expert Rev Neurother. 2006 Oct; 6(10):1465-79.
View in: PubMed

Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol. 2007 Feb; 81(3):271-7.
View in: PubMed

Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, Jänne PA, Johnson BE. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 2006 Sep 20; 24(27):4517-20.
View in: PubMed

Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C, Prados MD. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res. 2006 Aug 15; 12(16):4899-907.
View in: PubMed

Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, Yung WK, Aldape K, Wright J, Lamborn KR, Prados MD. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2006 Aug 01; 24(22):3651-6.
View in: PubMed

Doherty L, Gigas DC, Kesari S, Drappatz J, Kim R, Zimmerman J, Ostrowsky L, Wen PY. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology. 2006 Jul 11; 67(1):156-8.
View in: PubMed

Wen PY, Schiff D, Kesari S, Drappatz J, Gigas DC, Doherty L. Medical management of patients with brain tumors. J Neurooncol. 2006 Dec; 80(3):313-32.
View in: PubMed

Hochberg FH, Supko J, Amato A, Salem N, Carminati P, Wen P. Phase I trial and pharmacokinetic study of oral gimatecan in adults with malignant glioma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1559.
View in: PubMed

Kesari S, Schiff D, Doherty L, Gigas D, Batchelor T, Muzikansky A, O'Neill A, Drappatz J, Kieran M, Wen PY. Phase II study of antiangiogenic (metronomic) chemotherapy for recurrent malignant gliomas. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1569.
View in: PubMed

Chang SM, Lamborn K, Wen P, Deangelis L, Fink K, Lieberman F, Yung A, Robins I, Cloughesy T, Junck L, Prados M. Phase II study of POLY-ICLC in recurrent anaplastic glioma-A North American Brain Tumor Consortium study. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1550.
View in: PubMed

Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006 Jul 01; 24(19):3113-20.
View in: PubMed

Wen PY, Kesari S, Drappatz J. Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment. Expert Rev Anticancer Ther. 2006 May; 6(5):733-54.
View in: PubMed

Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2006 Apr; 8(2):189-93.
View in: PubMed

Reardon DA, Wen PY. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist. 2006 Feb; 11(2):152-64.
View in: PubMed

Wen PY, Yung WKA, Lamborn K, Cloughesy T, DeAngelis LM, Fine H, Chang S, Robins HI, Fink K, Abrey L, Lassman A, Mehta M, Kim L, Stiles C, Egorin M, Capdeville R, Kaplan R, Murgo A, Prados MD. Phase II Study of Imatinib Mesylate (STI571) for Patients with Recurrent Meningiomas (NABTC 01-08). Socity for Neuro-Oncology 11th Annual Meeting. 2006.
View in: PubMed

Kesari S, Ramakrishna N, Sauvageot C, Stiles CD, Wen PY. Targeted molecular therapy of malignant gliomas. Curr Oncol Rep. 2006 Jan; 8(1):58-70.
View in: PubMed

Hochberg FH, Supko JG< Amato A, Salem N, Zhang D, Carminati P, Wen PY, Szylleyko O. A Phase I Clinical Trial and Phamacokinetic Study of Oral ST1481 in Adults with Malignant Glioma. Proc ASCO. 2006.
View in: PubMed

Shah GD, Kesari S, Xu R, Batchelor TT, O'Neill AM, Hochberg FH, Levy B, Bradshaw J, Wen PY. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro Oncol. 2006 Jan; 8(1):38-46.
View in: PubMed

Sauvageot C, Barnes J, Wetherbee J, Ramakrishna N, Kung A, Kesari S, Stiles C, Kieran M, Wen PY. Effects of the HSP90 Inhibitor 17-AAG in Glioblastoma Multiforme. Internation Brain Tumor Research and Therapy Meeting. 2006.
View in: PubMed

Wen PY, Kesari S, Grier J. Neurologic complications of chemotherapy. Medlink. 2006.
View in: PubMed

Medical Management of Brain Tumors. 2006.
View in: PubMed

Wen PY, Chang SM< Kuhn J, Lamborn K, Robins HI, Cloughesy T, Gilbert MR, Yung WKA, Mehta M, DEAngelis LM, Abrey LE, Kesari S, Drappatz J, Lassman A, Dancey J, Prados MD. Phase I study of erlotinib and temsirolimus in patients with recurrent malignant gliomas (NABTC 04-02). Society for Neuro-Oncology 11th Annual Meeting. 2006.
View in: PubMed

Wen PY. Handbook fo Chemotherapy for Brain Tumors [book review]. Oncology. 2006; 20:430.
View in: PubMed

Targeted Molecular Therapies for Brain Tumors. 2006.
View in: PubMed

Barnes J, Sauvageot C, Kung A, Ramakrishna N, Stiles C, Chaponis D, Wen PY, Kieran M. SCH66336 (Sarasar(R)), an Oral Farnesyl Transferase Inhibitor, Synergizes with Temozolomide and Radiation Therapy for Orthotopic Malignant Gliomas. International Brain Tumor Research and Therapy Meeting. 2006.
View in: PubMed

Sauvageot C, Barnes J, Weatherbee J, Ramakrishna N, Kung A, Kesari S, Stiles c, Kieran M, Wen PY. Effects of the HSP90 Inhibitor 17-AAG inGlioblastoma Multiforme. Society for Neuro-Oncology 11th Annual Meeting. 2006.
View in: PubMed

Barnes JW, Cervi D, Ligon KL, Tseng KL, Longtine J A, Chaponis DM, Wen PY, Kesaris, Drappatz J, Black PM, Kieran MW. High throughput proteomic identification and quantification of MGMT in human brain tumors. Society for Neuro-Oncology 11th Annual Meeting. 2006.
View in: PubMed

Ramakrishna N, O'Halloran M, Sullivan S, Kesari S, Wen PY, Bachoo R, Stiles CD. The alkylphospholipd perifosine inhibits Akt and sensitezes murine and human glioma cells to radiation in in vitro and in vivo. Society for Neuro-Oncology 11th Annual Meeting. 2006.
View in: PubMed

Norden AD, Wen PY, Kesari S. Brain metastases. Curr Opin Neurol. 2005 Dec; 18(6):654-61.
View in: PubMed

Lassman AB, Rossi MR, Raizer JJ, Razier JR, Abrey LE, Lieberman FS, Grefe CN, Lamborn K, Pao W, Shih AH, Kuhn JG, Wilson R, Nowak NJ, Cowell JK, DeAngelis LM, Wen P, Gilbert MR, Chang S, Yung WA, Prados M, Holland EC. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res. 2005 Nov 01; 11(21):7841-50.
View in: PubMed

Cloughesy TF, Kuhn J, Robins HI, Abrey L, Wen P, Fink K, Lieberman FS, Mehta M, Chang S, Yung A, DeAngelis L, Schiff D, Junck L, Groves M, Paquette S, Wright J, Lamborn K, Sebti SM, Prados M. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2005 Sep 20; 23(27):6647-56.
View in: PubMed

Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, Prados MD. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005 Aug; 23(4):357-61.
View in: PubMed

Lu C, Gonzalez RG, Jolesz FA, Wen PY, Talcott JA. Suspected spinal cord compression in cancer patients: a multidisciplinary risk assessment. J Support Oncol. 2005 Jul-Aug; 3(4):305-12.
View in: PubMed

Wen PY, Schiff D, Doherty L, Gigas D, Musikansky A, Bradshaw J, Levy B, Kesari S, Ramakrishna N, Maher E, Black P. A phase II study of prolonged daily temozolomide for low-grade glioma. J Clin Oncol. 2005 Jun; 23(16_suppl):1522.
View in: PubMed

Kesari S, Ramakrishna N, Sauvageot C, Stiles CD, Wen PY. Targeted molecular therapy of malignant gliomas. Curr Neurol Neurosci Rep. 2005 May; 5(3):186-97.
View in: PubMed

Wen PY. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res. 2005 Mar 01; 11(5):1685-6.
View in: PubMed

Kesari S, Wen PY. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial [commentary]. Neurology. 2005; 64.
View in: PubMed

Drappatz J, Wen PY. Management of vasogenic edema in patients with brain tumors. Up-To-Date. 2005.
View in: PubMed

Drappatz J, Wen PY. Management of seizures in patients with primary and metastatic brain tumors. UpToDate. 2005.
View in: PubMed

Wen PY, Loeffler JS. Overview of brain metastases. Up-to-Date. 2005.
View in: PubMed

Reardon DA, Wen P, Lyons P, Knowles HL, Bedrosian CL, Friedman H. A Phase I trial of AP23573, a novel mTOR Inhibitor in patients with recurrent malignant glioma. AARC-NCI-EORTC Internation Conference on Melecular Targets and Cancer Therapeutics. 2005.
View in: PubMed

Update of Radiosurgery for Brain Metastases. Update of Radiosurgery for Brain Metastases. 2005.
View in: PubMed

Wen PY, Teoh SK, gigas DC, Macdonald LM. Presentations and Approaches to Patients with Brain Tumors. Schiff D, O'Neil BP, editors. cancer in the Nervous System. 2005.
View in: PubMed

Wen PY, Loeffler JS. Treatment of Brain Metastases in poor prognosis patients. Up-To-Date. 2005.
View in: PubMed

Lassman AB, Ross MR, Razier JR, Abrey LA, Grefe CN, Lamborn K, Pao W, Shih AH, Wilson R, Nowak NJ, Cowell JK, DeAngelis LM, Wen P, Gilbert MR, Chang S, Yung WKA, Prados M, Holland EC. Molecular study of malignant gliomas treated with the EGFR inhibitor, elotinib (OSI-774): Tissue analysis from a North American Brain Tumor Consortium (NABTC) study. Clin Cancer Res. 2005; 11:7841-7850.
View in: PubMed

Wen PY, Schiff D, doherty L, Gigas DC, Musikansky A, Bradshaw J, Levy B, Kesari S, Ramakrishna N, Maher EA, Black PM. A Phase II Study of Prolonged Daily Temozolomide for Low-Grade Glioma. Proc ASCO. 2005.
View in: PubMed

Richardson P, Chanan-Khan A, Schlossman R, Munshi N, Wen PY, Kesari S, Briemberg H, Kuter D, Oaklander A, Lonial S, Hassoun H, Doss D, Lunde L, Dinand K, McAlister C, Warren D, Collins D, Esseltine D, Amato A, Anderson KC. A Multicenter Phase II Trial of Bortezomib in Patients with Previously Untreated Multiple Myeloma: Efficacy with Manageable Toxicity in Patients with Unexpectedly Hgi9h Rates of Baseline Peripheral Neuropathy. American Society for Hematology 47th Annual Meeting. 2005.
View in: PubMed

Wen PY, Loeffler JS. Treatment of brain metastases in good prognosis patients. Up-To-Date. 2005.
View in: PubMed

bolar TS, Benner T, Hodge RD, Pectasides M, Wiggins CJ, George DJ, Wen PY, Sorenson AG. Perfusion Imaging of Hemangioblastoma: Implications for using arterial spin labeling to characterize tumor dynamics. ISMR. 2005.
View in: PubMed

Drappatz J, Wen PY. Chemotherapy for brain metastases. Up-To-Date. 2005.
View in: PubMed

Wen PY, MacDonald L, Gigas DC. Management of non-neoplastic problems in brain tumor patients. Black PM, Loeffler JS, editors. Cancer of Nervous System. 2005; 243-254.
View in: PubMed

Drappatz J, Wen PY. Palliative Care in Neurology, Oxford Press 2004. Voltz et al. (eds) [book review]. j Palliative Care. 2005; 8:1067-8.
View in: PubMed

Hart RG, Wen PY. Anticoagulant and antiplatelet therapy in patients with brain tumors. UpToDate. 2005.
View in: PubMed

Targeted Molecular Therapies for Malignant Gliomas. 2005.
View in: PubMed

Drappatz J, Wen PY. Palliative Care Consultations- Primary and metastatic brain tumours, Oxford Press, 2005, Booth and Bruera (eds) [book review]. J Palliative Care. 2005; (8):1068-9.
View in: PubMed

Wen PY. Cnetral Nervous system Tumors. American Society of Clincial Oncology 2005 Annual Meeting Summaries. 2005; 32-40.
View in: PubMed

Cloughesy TF, Kuhn J, Robins HI, Abrey A, Wen P, Fink K, Lieberman FS, Mehta M, Chang S, Yung A, DeAngelis L, Schiff D, Junck L, Groves M, Wright J, Lamborn K, Sebti S, Prados, M. A Phase I Trial of R115777 in Patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs (EIAEDs): A North American Brian Tumor Consortium Study. J Clin Oncol. 2005; (23):6647-6656.
View in: PubMed

Yung WKA, Lieberman FS, Wen P, et al. Combination of Temozolomide and Irinotecan showed enhanced activity for recurrent malignant gliomas: A North American Brain Tumor Consoritum (NABTC) Phase II study. Proc ASCO. 2005.
View in: PubMed

Drappatz J, Wen PY. Non-cytotoxic drugs as potential treatments for gliomas. Curr Opin Neurol. 2004 Dec; 17(6):663-73.
View in: PubMed

Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, Liu V, Mehta MP, Nicholas MK, Prados M. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol. 2004 Nov 01; 22(21):4282-9.
View in: PubMed

Chang SM, Kuhn J, Wen P, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, Cloughesy T, De Angelis L, Razier J, Hess K, Dancey J, Prados MD. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs. 2004 Nov; 22(4):427-35.
View in: PubMed

Mrugala MM, Kesari S, Ramakrishna N, Wen PY. Therapy for recurrent malignant glioma in adults. Expert Rev Anticancer Ther. 2004 Oct; 4(5):759-82.
View in: PubMed

Shah G, Kesari S, Xu R, Henson J, Batchelor T, Hochberg F, Oneill A, Levy B, Bradshaw J, Wen PY. Comparison of 1D, 2D, 3D and volumetric parameters in measuring tumor response in high-grade gliomas in adults. J Clin Oncol. 2004 Jul 15; 22(14_suppl):1523.
View in: PubMed

Raizer JJ, Abrey LE, Wen P, Cloughesy T, Robins IA, Fine HA, Lieberman F, Puduvalli VK, Fink KL, Prados M. A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. J Clin Oncol. 2004 Jul 15; 22(14_suppl):1502.
View in: PubMed

Lieberman FS, Cloughesy T, Fine H, Kuhn J, Lamborn K, Malkin M, Robbins HI, Yung WA, Wen P, Prados M. NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas. J Clin Oncol. 2004 Jul 15; 22(14_suppl):1510.
View in: PubMed

Prados M, Yung W, Wen P, Junck L, Fink K, Cloughesy T, Robins I, Chang S, Kuhn J. Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A study of the North American Brain Tumor Consortium. J Clin Oncol. 2004 Jul 15; 22(14_suppl):1504.
View in: PubMed

Supko JG, Alderson L, Wen P, Cassidy K, Pace S, Obrocea M, Hochberg F. Pharmacokinetics of gimatecan, and orally administered camptothecin analogue, in patients with malignant gliomas. J Clin Oncol. 2004 Jul 15; 22(14_suppl):2039.
View in: PubMed

Wen PY, Kesari S. Malignant gliomas. Curr Neurol Neurosci Rep. 2004 May; 4(3):218-27.
View in: PubMed

Brain Metastases-Emerging role of Radiosurgery. 2004.
View in: PubMed

Raizer JJ, Abrey L, Wen P, Cloughesy T, Robins IA, Fine HA, Lieberman F, Puduvalli VK, Fink KL, Prados M. A Phase II trial of OSI-774 (Tarceva) in patients with Recurrent Malignant Gliomas not on EIAEDs. Proc ASCO. 2004.
View in: PubMed

Supko JG, Alderson L, Wen P, Cassidy K, Pace S, Obrocea M, Hochberg F. Pharmacokinetics of gimatecan and orally administerd camptothecin analogue, in patients with malignant gliomas. Proc ASCO. 2004.
View in: PubMed

Wen PY, Kesari S, Hsu L, De Girolami U. Brain Tumors. Baker and Joynt's Clinical Neurology on CD-ROM. 2004.
View in: PubMed

Wen PY, Ramakrishna N, Fisher DC. Neurologic complications of lymphoma therapy. Batchelor TT, editor. Nervous System Lymphoma. 2004; 149-182.
View in: PubMed

Prados M, Yung W, Wen P, Junck L, Fink K, Cloughesy T, Robins IA , Chang S, Kuhn J. Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A North American Brain Tumor Consortium study. Proc ASCO. 2004.
View in: PubMed

Neurologic Complications of Cancer Therapy. 2004.
View in: PubMed

Ramakrishna N, Galper S, Wen PY. Brain Metastases in patients with breast cancer. Harris J, Lippman M, Morrow M, Kent Osborne C, editors. Diseases of the Breast. 2004; 1205-1218.
View in: PubMed

Schiff D, Wen PY. Nervous system metastases. Bradley W, Daroff R, Fenichel G, Jankovic J, editors. Neurology in Clinical Practice. 2004; 1441-1460.
View in: PubMed

Richardson PG, Chana-Khan A, Schlossman R, Munshi M, Wen PY, Briemberg H, Kuter K, Oaklander A-L, Lonial S, Hassoun H, Doss D, Lunde L, Dinand K, McAlister C, Warren D, Collins D, Esseltine D, Amato A, Anderson KC. Phase II Trial of Single Agent VELCADE (bortezomib) in patients with previously untreated multiple myeloma. American Society for Hematology 46th Annual Meeting. 2004.
View in: PubMed

Lieberman F, Cloughesy T, Fine H, Kuhn J, Lamborn K, Malkin M, Robbins HI, Yung WA, Wen P, Prados M. NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas. Proc ASCO. 2004.
View in: PubMed

Cavaliere R, Farace E, Wen P, Schiff D. Thalidomide-induced thromboembolic events in patients with high-grade gliomas. Neuro-Oncology. 2004; Abstr TA-11.
View in: PubMed

Voloshcin AD, Wen PY, Lawler B, Ciordia R, Hochberg FH, Batchelor TT. Topotecan as salvage therapy for refractory or relapsed primary central nervous system lymphoma: Final Report. American Academy of Neuorlogy, 56th Annual Meeting. 2004.
View in: PubMed

Prados MD, Yung WK, Jaeckle KA, Robins HI, Mehta MP, Fine HA, Wen PY, Cloughesy TF, Chang SM, Nicholas MK, Schiff D, Greenberg HS, Junck L, Fink KL, Hess KR, Kuhn J. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2004 Jan; 6(1):44-54.
View in: PubMed

Kesari S, Wen PY. Neuro-Oncology. Samuels MA, editor. Manual of Neurologic Therapeutics. 2004; 115-178.
View in: PubMed

Wen PY, gigas DC, MacDonald L, Batchelor TT, Schiff D, Xu R, Ramakrishna N, Weaver S, Kracher J, Bradshaw J, Levy B, Bailey E, Kesari S, Maher EA, Henson J, Black PM. Phase II Study of Temozolomide, Thalidomide and Celecoxib in Patients with Newly-Diagnosed Glioblastomas Multiforme in the Post-Radiation Setting. Neuro-Oncology. 2004; Abstr. TA-64.
View in: PubMed

Wen PY, McColl CD, Freilich RJ. Epidural disease. Harris J, Lippman M, Morrow M, Kent Osborne C, editors. Diseases of the Breast. 2004; 1219-1231.
View in: PubMed

Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, Figg WD, Purow BW, Borkowf CB. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol. 2003 Jun 15; 21(12):2299-304.
View in: PubMed

Wen PY, Schiff D. Neurologic complications of solid tumors. Neurol Clin. 2003 Feb; 21(1):107-40, viii.
View in: PubMed

Plotkin SR, Wen PY. Neurologic complications of cancer therapy. Neurol Clin. 2003 Feb; 21(1):279-318, x.
View in: PubMed

Wen PY, Glantz MJ. Neurologic complications of cancer. Preface. Neurol Clin. 2003 Feb; 21(1):xi-xiii.
View in: PubMed

Lieberman, Cloughesy T, Deangelis L, Fine H, Fink K, Junck L, Kuhn J, Mehta M, Wen P, Prados M. Phase I-II study of ZD-1839 for recurrent malignant gliomas and meningiomas progressing after radiation therapy. ASCO. 2003.
View in: PubMed

Gilber MR, Wen P, Lieberman F, Robins I, Mehta M, Yung WKA, Chang S, Junck L, Cloughesy T, Prados M. Phase I/II study of combination temozolomide (TMZ) and irinotecan (CPT-11) for recurrent malignant gliomas: A North American Brain Tumor Consurotium (NABTC) study. ASCO. 2003.
View in: PubMed

Plotkin S, Wen PY. Brain Metastases. Samuels MA, Feske S, editors. Office Practice of Neurology. 2003; 1134-1140.
View in: PubMed

Wen PY, Ramakrishna, N. General principles of management of patients with brain tumors. Samuels MA, Feske S, editors. Office Practice of Neurology. 2003; 1018-1024.
View in: PubMed

Alderson L, Supko J, Hochberg F, Wen P, Maestri X, Sampath P, Benincasa E, Belonogova N, Zanna C, Carminati P, Chabner B, Calabresi P. Phase I/II trial of gimatecan in patients with recurrent maligngant glioma. Neuro Oncology. 2003; 5:347. Abstr TA-01.
View in: PubMed

Wen PY. CNS complications of Cancer Therapy. Schiff D, Wen P, editors. Cancer Neurology in Clinical Practice. 2003; 215-231.
View in: PubMed

Wen PY, Glantz MJ, editors. Neurologic Complications of Cancer. Neurol Clinics. 2003.
View in: PubMed

Schiff D, Wen PY, Hsu L. Uncommon brain tumors, skull base tumors, and intracranial cysts. Samuels MA, Feske S, editors. Office Practice of Neurology. 2003; 1092-1100.
View in: PubMed

Schiff D, Trump D, Wen P. Neurologic Complications of Genitourinary Malignancies. Schiff D, Wen PY, editors. Cancer Neurology in Clinical Practice. 2003; 327-338.
View in: PubMed

Wen PY. Neurologic complications of chemotherapy. Samuels MA, Feske S, editors. Office Practice of Neurology. 2003; 1134-1140.
View in: PubMed

Brain Metastases-Emerging Role of Radiosurgery. 2003.
View in: PubMed

Wen PY, Fine HA, Loeffler JS, Black P. Malignant Gliomas. Samuels MA, Feske S, editors. Office Practice of Neurology. 2003; 1038-1048.
View in: PubMed

Wen PY. Neurologic complications of bone marrow transplantation. Samuels MA, Feske S, editors. Office Practice of Neurology. 2003; 1166-1171.
View in: PubMed

Wen PY, Kesari S. Neurologic complications of chemotherapy. Medlink Neurology. 2003.
View in: PubMed

Schiff D, Wen PY, editors. Cancer Neurology in Clinical Practice. 2003.
View in: PubMed

Plotkin S, Wen PY. Brain Metastases. Samuels MA, Feske S, editors. Office Practice of Neurology. 2003; 1101-1107.
View in: PubMed

Wen PY, Schiff D, MacDonald L, Gigas DC, Ramakrishna N, Batchelor TT, Xu R, Slate A, Levy B, Bradshaw J, Black PM, Folkman J, Kieran M. Phase II Study of Antiangiogenic Chemotherapy for Recurrenct Malignant Glioma. Neuro-Oncology. 2003; 5:357. Abstr TA-41.
View in: PubMed

Wen PY. Encephalopathy and Neuropathy. Furie B, Atkins M, Cassieth P, Mayer R, editors. Clinical Practice of Hematology-Oncology: Presentations, Diagnosis and Treatment. 2003; 32-41.
View in: PubMed

Wen PY, Teoh SK. Clinical Presentation and Diagnosis of Brain Tumors. Samuels MA, Fesk S, editors. Office Practice of Neurology. 2003; 1013-1017.
View in: PubMed

Jeter MD, Jänne PA, Brooks S, Burstein HJ, Wen P, Fuchs CS, Loeffler JS, Devlin PM, Salgia R. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys. 2002 Jun 01; 53(2):394-400.
View in: PubMed

Wen PY, Marks PW. Medical management of patients with brain tumors. Curr Opin Oncol. 2002 May; 14(3):299-307.
View in: PubMed

PY Wen. Brain Metastases. Up-To-Date in Oncology. 2002.
View in: PubMed

PY Wen, Bachoo R. Management of Brain Tumors. Up-To-Date in Oncology. 2002.
View in: PubMed

Plotkin S, PY Wen. Neurologic complications of cancer therapy. Up-To-Date in Oncology. 2002.
View in: PubMed

Blankenberg FG, Wen P, Dai M, Zhu D, Panchal SN, Tait JF, Post AM, Strauss HW, Valantine HA. Detection of early atherosclerosis with radiolabeled monocyte chemoattractant protein-1 in prediabeteic Zucker rats. Pediatr Radiol. 2001 Dec; 31(12):827-35.
View in: PubMed

Cantin B, Wen P, Zhu D, Dai M, Panchal SN, Billingham ME, Gwathmey JK, Valantine HA. Transplant coronary artery disease: a novel model independent of cellular alloimmune response. Circulation. 2001 Nov 20; 104(21):2615-9.
View in: PubMed

Schiff D, O'Neill B, Wijdicks E, Antin JH, Wen PY. Gliomas arising in organ transplant recipients: an unrecognized complication of transplantation? Neurology. 2001 Oct 23; 57(8):1486-8.
View in: PubMed

Baki L, Marambaud P, Efthimiopoulos S, Georgakopoulos A, Wen P, Cui W, Shioi J, Koo E, Ozawa M, Friedrich VL, Robakis NK. Presenilin-1 binds cytoplasmic epithelial cadherin, inhibits cadherin/p120 association, and regulates stability and function of the cadherin/catenin adhesion complex. Proc Natl Acad Sci U S A. 2001 Feb 27; 98(5):2381-6.
View in: PubMed

Wen PY, Black PM, Loeffler JS. Metastatic Brain Cancer. DeVita VT, Hellman S, Rosenberg SA, editors. Principles and Practice of Oncology. 2001; 2655-2670.
View in: PubMed

Wen PY, Teoh SK, Black PM. Clinical Imaging and Diagnosis of Brain Tumors. Laws E, Kaye A, editors. Brain Tumors. 2001; 217-248.
View in: PubMed

Park CC, Hartmann C, Folkerth R, Loeffler JS, Wen PY, Fine HA, Black PM, Shafman T, Louis DN. Systemic metastasis in glioblastoma may represent the emergence of neoplastic subclones. J Neuropathol Exp Neurol. 2000 Dec; 59(12):1044-50.
View in: PubMed

Wen PY, Loeffler JS. Brain metastases. Curr Treat Options Oncol. 2000 Dec; 1(5):447-58.
View in: PubMed

Vorachek WR, Steppan CM, Lima M, Black H, Bhattacharya R, Wen P, Kajiyama Y, Locker J. Distant enhancers stimulate the albumin promoter through complex proximal binding sites. J Biol Chem. 2000 Sep 15; 275(37):29031-41.
View in: PubMed

Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, Grossman SA, Cairncross JG. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000 May 23; 54(10):1886-93.
View in: PubMed

Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol. 2000 Feb; 18(4):708-15.
View in: PubMed

wen PY, Shafman T. Brain metastases in patients with breast cancer. Harris J, Lippman M, Morrow M, Kent Osborne C, editors. Disease of the Breast. 2000.
View in: PubMed

Glanz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, Grossman SA, Cairncross JG. Practice parameters: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neurology. 2000; 54:1886-1893.
View in: PubMed

Wen PY, Loeffler JS. Management of brain metastases. Oncology (Williston Park). 1999 Jul; 13(7):941-54, 957-61; discussion 961-2, 9.
View in: PubMed

Mamon HJ, Wen PY, Burns AC, Loeffler JS. Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation therapy. Epilepsia. 1999 Mar; 40(3):341-4.
View in: PubMed

Mao H, Zhang L, Wang Y, Wen P, Cui S. [Influence of icariin on cell membrane of highly metastatic human lung tumor cell line]. Zhong Yao Cai. 1999 Jan; 22(1):35-6.
View in: PubMed

Wen PY, Black PB. Clinical Presentation, Evaluation and Preoperative Preparation of the Patient. Berger MS, Wilson CB, editors. Textbook of Gliomas. 1999; 328-344.
View in: PubMed

Wen PY. Spinal Ependymomas. Gilman S, Goldstein GW, Waxman SG, editors. Neurobase. 1999.
View in: PubMed

Shrieve DC, Alexander E, Black PM, Wen PY, Fine HA, Kooy HM, Loeffler JS. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg. 1999 Jan; 90(1):72-7.
View in: PubMed

Role of chemotherpay in patients with gliomas. 1999.
View in: PubMed

Talcott JA, Stomper PC, Drislane FW, Wen PY, Block CC, Humphrey CC, Lu C, Jolesz F. Assessing suspected spinal cord compression: a multidisciplinary outcomes analysis of 342 episodes. Support Care Cancer. 1999 Jan; 7(1):31-8.
View in: PubMed

Lu C, Stomper PC, Drislane FW, Wen PY, Block CC, Humphrey CC, Collins CA, Jolesz F, Talcott JA. Suspected spinal cord compression in breast cancer patients: a multidisciplinary risk assessment. Breast Cancer Res Treat. 1998 Sep; 51(2):121-31.
View in: PubMed

Lea-Currie YR, Wen P, McIntosh MK. Dehydroepiandrosterone reduces proliferation and differentiation of 3T3-L1 preadipocytes. Biochem Biophys Res Commun. 1998 Jul 30; 248(3):497-504.
View in: PubMed

Manome Y, Kunieda T, Wen PY, Koga T, Kufe DW, Ohno T. Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine. Hum Gene Ther. 1998 Jul 01; 9(10):1409-17.
View in: PubMed

Kassis AI, Wen PY, Van den Abbeele AD, Baranowska-Kortylewicz J, Makrigiorgos GM, Metz KR, Matalka KZ, Cook CU, Sahu SK, Black PM, Adelstein SJ. 5-[125I]iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats. J Nucl Med. 1998 Jul; 39(7):1148-54.
View in: PubMed

Schiff D, Batchelor T, Wen PY. Neurologic emergencies in cancer patients. Neurol Clin. 1998 May; 16(2):449-83.
View in: PubMed

Parr MJ, Wen PY, Schaub M, Khoury SJ, Sayegh MH, Fine HA. Immune parameters affecting adenoviral vector gene therapy in the brain. J Neurovirol. 1998 Apr; 4(2):194-203.
View in: PubMed

Hakim R, Alexander E, Loeffler JS, Shrieve DC, Wen P, Fallon MP, Stieg PE, Black PM. Results of linear accelerator-based radiosurgery for intracranial meningiomas. Neurosurgery. 1998 Mar; 42(3):446-53; discussion 453-4.
View in: PubMed

Apergis GA, Crawford N, Ghosh D, Steppan CM, Vorachek WR, Wen P, Locker J. A novel nk-2-related transcription factor associated with human fetal liver and hepatocellular carcinoma. J Biol Chem. 1998 Jan 30; 273(5):2917-25.
View in: PubMed

Chang EL, Loeffler JS, Riese NE, Wen PY, Alexander E, Black PM, Coleman CN. Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma. Int J Radiat Oncol Biol Phys. 1998 Jan 01; 40(1):65-70.
View in: PubMed

Feske S, Wen PY, editors. Emergency Neurology. Neurologic clinics. 1998.
View in: PubMed

Wen PY, Alyea EP, Simon D, Herbst RS, Soiffer RJ, Antin JH. Guillain-Barré syndrome following allogeneic bone marrow transplantation. Neurology. 1997 Dec; 49(6):1711-4.
View in: PubMed

Tomashefski JF, Wen P, Giampoli E, Doershuk CF, Stern RC, Dahms B. Pulmonary intralobar sequestration in a patient with cystic fibrosis. Hum Pathol. 1997 Dec; 28(12):1436-9.
View in: PubMed

Lea-Currie YR, Wen P, McIntosh MK. Dehydroepiandrosterone-sulfate (DHEAS) reduces adipocyte hyperplasia associated with feeding rats a high-fat diet. Int J Obes Relat Metab Disord. 1997 Nov; 21(11):1058-64.
View in: PubMed

Parr MJ, Manome Y, Tanaka T, Wen P, Kufe DW, Kaelin WG, Fine HA. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med. 1997 Oct; 3(10):1145-9.
View in: PubMed

Wen PY, Feske SK, Teoh SK, Stieg PE. Cerebral hemorrhage in a patient taking fenfluramine and phentermine for obesity. Neurology. 1997 Aug; 49(2):632-3.
View in: PubMed

Tanaka T, Manome Y, Wen P, Kufe DW, Fine HA. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med. 1997 Apr; 3(4):437-42.
View in: PubMed

Fine HA, Wen PY, Robertson M, O'Neill A, Kowal J, Loeffler JS, Black PM. A phase I trial of a new recombinant human beta-interferon (BG9015) for the treatment of patients with recurrent gliomas. Clin Cancer Res. 1997 Mar; 3(3):381-7.
View in: PubMed

Sahu SK, Wen PY, Foulon CF, Nagel JS, Black PM, Adelstein SJ, Kassis AI. Intrathecal 5-[125I]iodo-2'-deoxyuridine in a rat model of leptomeningeal metastases. J Nucl Med. 1997 Mar; 38(3):386-90.
View in: PubMed

Lynch TJ, Lambert JM, Coral F, Shefner J, Wen P, Blattler WA, Collinson AR, Ariniello PD, Braman G, Cook S, Esseltine D, Elias A, Skarin A, Ritz J. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. J Clin Oncol. 1997 Feb; 15(2):723-34.
View in: PubMed

Wen PY, Fine HA. Leptomeningeal Metastases. Black PMcL, Loeffler JS, editors. Cancer of the Nervous System. 1997; 288-309.
View in: PubMed

Wen PY. Diagnosis of Management of Brain Tumors. Black PMcL, Loeffler JS, editors. Cancer of the Nervous System. 1997; 106-127.
View in: PubMed

Packard AB, Barbarics E, Kronauge JF, Wen PY, Day PJ, Jones AG. Comparison of uptake of 99mTc-alkylisonitriles in the rat 9L gliosarcoma tumor model. Nucl Med Biol. 1997 Jan; 24(1):21-5.
View in: PubMed

Wen PY. Neurologic Complications of Chemotherapy. Gilman S, Goldstein GW, Waxman SG, editors. Neurobase. 1997.
View in: PubMed

Tanaka T, Manome Y, Wen PY, Kufe D, Fine HA. Retroviral-meicated transduction of a modified platelet factor-4 cDNA inhibits angiogenesis and tumor growth. Nature Medicine. 1997; 3:437-442.
View in: PubMed

Manome Y, Wen PY, Chen L, Tanaka T, Dong Y, Yamazoe M, Hirshowitz A, Kufe DW, Fine HA. Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide. Gene Ther. 1996 Jun; 3(6):513-20.
View in: PubMed

Manome Y, Wen PY, Dong Y, Tanaka T, Mitchell BS, Kufe DW, Fine HA. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat Med. 1996 May; 2(5):567-73.
View in: PubMed

Dong Y, Wen P, Manome Y, Parr M, Hirshowitz A, Chen L, Hirschowitz EA, Crystal R, Weichselbaum R, Kufe DW, Fine HA. In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. Hum Gene Ther. 1996 Apr 10; 7(6):713-20.
View in: PubMed

Kassis AI, Tumeh SS, Wen PY, Baranowska-Kortylewicz J, Van den Abbeele AD, Zimmerman RE, Carvalho PA, Garada BM, DeSisto WC, Bailey NO, Castronovo FP, Mariani G, Black PM, Adelstein SJ. Intratumoral administration of 5-[123I]iodo-2'-deoxyuridine in a patient with a brain tumor. J Nucl Med. 1996 Apr; 37(4 Suppl):19S-22S.
View in: PubMed

Neurologic complications of cancer. 1996.
View in: PubMed

Management of Patients with brain tumors. 1996.
View in: PubMed

Gaa J, Warach S, Wen P, Thangaraj V, Wielopolski P, Edelman RR. Noninvasive perfusion imaging of human brain tumors with EPISTAR. Eur Radiol. 1996; 6(4):518-22.
View in: PubMed

Schiff D, Wen PY. Uncommon brain tumors. Neurol Clin. 1995 Nov; 13(4):953-74.
View in: PubMed

Wen PY, Fine HA, Black PM, Shrieve DC, Alexander E, Loeffler JS. High-grade astrocytomas. Neurol Clin. 1995 Nov; 13(4):875-900.
View in: PubMed

Geller EB, Wen PY. Migraine with aura as the presentation of leukemia. Headache. 1995 Oct; 35(9):560-2.
View in: PubMed

Manome Y, Wen PY, Hershowitz A, Tanaka T, Rollins BJ, Kufe DW, Fine HA. Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors. Cancer Immunol Immunother. 1995 Oct; 41(4):227-35.
View in: PubMed

Loeffler JS, Shrieve DC, Wen PY, Fine HA, Kooy HM, Addesa AE, Black PM, Alexander E. Radiosurgery for Intracranial Malignancies. Semin Radiat Oncol. 1995 Jul; 5(3):225-234.
View in: PubMed

Jin JR, Wen P, Locker J. Enhancer sharing in a plasmid model containing the alpha-fetoprotein and albumin promoters. DNA Cell Biol. 1995 Mar; 14(3):267-72.
View in: PubMed

Shrieve DC, Alexander E, Wen PY, Fine HA, Kooy HM, Black PM, Loeffler JS. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery. 1995 Feb; 36(2):275-82; discussion 282-4.
View in: PubMed

Alexander E, Moriarty TM, Davis RB, Wen PY, Fine HA, Black PM, Kooy HM, Loeffler JS. Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst. 1995 Jan 04; 87(1):34-40.
View in: PubMed

Black PM, Wen PY, editors. Brain Tumors in Adults. Neurologic Clinics. 1995.
View in: PubMed

Wen PY, Black PMcL. Introduction to Brain Tumors in Adults. Neurologic Clinics. 1995; 13:953-974.
View in: PubMed

Wen PY, Schiff D, Hsu L. Uncommon brain tumors and intracranial cysts. Samuels MA, Feske S, editors. Office Practice of Neurology. 1995; 887-892.
View in: PubMed

Swoboda K, Wen PY. Neurologic complications of bone marrow transplantation and graft versus host disease. Samuels MA, Feske S, editors. Office Practice of Neurology. 1995; 944-948.
View in: PubMed

Wen PY. Clinical Presentation and Diagnosis of Brain Tumors. Samuels MA, Feske S, editors. Office Practice of Neurology. 1995; 813-817.
View in: PubMed

Moriarty TM, Loeffler JS, Black PMcL, Wen PY, Fine HA, Kooy HM, Alexander E. Stereotactic radiosurgery for the treatment of brain metastases: an update. Alexander E, Kondzioloka D, Lindquist C, Loeffler JS, editors. Radiosurgery. 1995; 83-91.
View in: PubMed

Wen PY. Neurologic Complications of Chemotherapy. Samuels MA, Feske S, editors. Office Practice of Neurology. 1995; 914-919.
View in: PubMed

Neurologic complications of brain tumor therapy. 1995.
View in: PubMed

Uncommon Brain Tumors. 1995.
View in: PubMed

Non-metastatic complications of cancer. 1995.
View in: PubMed

Wen PY, Fine HA, Loeffler JS, Black P. Malignant Gliomas. Samuels MA, Feske S, editors. Office Practice of Neurology. 1995; 836-844.
View in: PubMed

Black PM, Wen P. Clinical Imaging and Laboratory Diagnosis of Brain Tumors. Kaye A, Shaw E, editors. Brain Tumors. 1995; 191-214.
View in: PubMed

Loeffler JS, Shrieve DS, alexander E, Kooy HN, Tarbell NJ, Stieg PE, Wen PY, Black PMcL. Stereotactic radiotherapy for meningiomas. Alexander E, Kondzioloka D, Lindquist C, Loeffler JS, editors. Radiosurgery. 1995; 1:47-54.
View in: PubMed

Hersh B, Dalmau J, Dan gond F, Geller E, Wen PY. Opsoclonus-myoclonus with anti-Hu antibody [letter]. Neurology. 1995; 45:1421.
View in: PubMed

Schwarz MS, Loeffler JS, Black PMcL, Shrieve DC, Wne PY, Fine HA, Alexander E. Reoperation following radiosurgery of gliobastoma: impact on survival and neurologic statuts. Alexander E, Kondzioloka D, Lindquist C, Loeffler JS, editors. Radiosurgery. 1995; 141-157.
View in: PubMed

Wen PY, Loeffler JS. Advances in the diagnosis and management of pituitary tumors. Curr Opin Oncol. 1995 Jan; 7(1):56-62.
View in: PubMed

Wen PY. General principles of management of patients with brain tumors. Samuels MA, Fesk S, editors. Office Practice of Neurology. 1995; 817-824.
View in: PubMed

Initial management of gliomas including diagnosis and prognosis. 1995.
View in: PubMed

Wen P, Locker J. A novel hepatocytic transcription factor that binds the alpha-fetoprotein promoter-linked coupling element. Mol Cell Biol. 1994 Oct; 14(10):6616-26.
View in: PubMed

Hersh B, Dalmau J, Dangond F, Gultekin S, Geller E, Wen PY. Paraneoplastic opsoclonus-myoclonus associated with anti-Hu antibody. Neurology. 1994 Sep; 44(9):1754-5.
View in: PubMed

Riese NE, Loeffler JS, Wen P, Alexander E, Black PM, Coleman CN. A phase I study of etanidazole and radiotherapy in malignant glioma. Int J Radiat Oncol Biol Phys. 1994 Jun 15; 29(3):617-20.
View in: PubMed

Wen PY, Alexander E, Black PM, Fine HA, Riese N, Levin JM, Coleman CN, Loeffler JS. Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas. Cancer. 1994 Jun 15; 73(12):3029-36.
View in: PubMed

Wen PY, Alexander E, Loeffler JS. Stereotactic radiosurgery treats intracranial lesions. Diagn Imaging (San Franc). 1994 May; 16(5):76-80, 107.
View in: PubMed

Management issues in brain tumor patients. 1994.
View in: PubMed

Riese NE, Rieker P, Wen P, Buswell L. A pilot study: Quality of Life in Pimary Brain Tumor Patients. Quality of Life Newsletter. 1994; 9:10.
View in: PubMed

Non-metastatic complications of cancer. 1994.
View in: PubMed

Epstein C, Lynch T, Shefner J, Wen P, Maxted D, Braman V, Ariniello P, Coral F, Ritz J. Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer. Int J Cancer Suppl. 1994; 8:57-9.
View in: PubMed

Epstein C, Lynch T, Shefner J, Wen P, Maxted D, Braman V, Arinello P, Coral F, Ritz J. Use of immunotoxin N901-blocked ricin in patients with small cell lung cancer. Int J Oncol. 1994; Supp 8:57-59.
View in: PubMed

Cross JC, Wen P, Rutter WJ. Transactivation by hepatitis B virus X protein is promiscuous and dependent on mitogen-activated cellular serine/threonine kinases. Proc Natl Acad Sci U S A. 1993 Sep 01; 90(17):8078-82.
View in: PubMed

Wen P, Shanti I. Use of cerebral imaging in patients with headaches. Arch Intern Med. 1993 Jul 12; 153(13):1613-4.
View in: PubMed

Levin JM, Schiff D, Loeffler JS, Fine HA, Black PM, Wen PY. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology. 1993 Jun; 43(6):1111-4.
View in: PubMed

Schiff D, Feske SK, Wen PY. Deceptively normal ventricular fluid in lymphomatous meningitis. Arch Intern Med. 1993 Feb 08; 153(3):389-90.
View in: PubMed

Slivka A, Wen PY, Shea WM, Loeffler JS. Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors. Am J Med. 1993 Feb; 94(2):216-9.
View in: PubMed

Paraneoplastic syndromes. 1993.
View in: PubMed

Black PMcL, Loeffler JS, Alexander E, Tarbell N, Fine HA, Wen PY, Scott RM, Sallan S, Moore MR. Hemispheric Stroglial Neoplasms in Adults and Children. Black PMcL, LSchoene WC, Lampson LA, editors. Astrocytomas. 1993; 151-165.
View in: PubMed

Wen P, Shanti I. Neuroimaging for headaches [letter]. Arch Int Med. 1993; 1613.
View in: PubMed

Wen, P. Clinical Experience with Immunotherapy. Black PMcL, Schoene WC, Lampson LA, editors. Astrocytomas. 1993; 123-150.
View in: PubMed

Alexander E, Black PMcL, Wen PY, Fine H, Loeffler JS. Results of radiosurgery versus brachytherapy for malignant gliomas. DeSalles AAF, Goetsch SJ, editors, Stereotactic surgery and radiosurgery. 1993; 455-461.
View in: PubMed

Non-CNS complications of brain tumors. 1993.
View in: PubMed

Wen PY, Schiff D. Clinical Evaluation of Patients with Astrocytomas. Black, PMcL, Schoene WC, Lampson LA, editors. Astrocytomas. 1993; 26-36.
View in: PubMed

Loeffler JS, Alexander E, Shea WM, Wen PY, Fine HA, Kooy HM, Black PM. Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol. 1992 Sep; 10(9):1379-85.
View in: PubMed

Wen P. Major histocompatibility antigens in murine tumors. J Neurosurg. 1992 Jun; 76(6):1048-50.
View in: PubMed

Wen PY, Blanchard KL, Block CC, Loeffler JS, Davis DG, Lacroix LA, Antin JH. Development of Lhermitte's sign after bone marrow transplantation. Cancer. 1992 May 01; 69(9):2262-6.
View in: PubMed

Sandson TA, Wen PY, LeMay M. Reversed cerebral asymmetry in women with breast cancer. Lancet. 1992 Feb 29; 339(8792):523-4.
View in: PubMed

Lampson LA, Wen P, Roman VA, Morris JH, Sarid JA. Disseminating tumor cells and their interactions with leukocytes visualized in the brain. Cancer Res. 1992 Feb 15; 52(4):1018-25.
View in: PubMed

Riese N, Coleman CN, Noll L, Buswell L, Loeffler J, Alexander E, Kooy H, Wen P, Harris JR, Howes A, Kramer R, Grisby P. A phpase 1 study of continuous infusion of etanidazole (SR2508) with brachytherapy. Int J Radiat Oncol Biol Phys. 1992; 22:577-580.
View in: PubMed

Non-surgical treatments of CNS malignancies. 1992.
View in: PubMed

Wen P. MHC expression in murine tumors [letter]. J Neurosurg. 1992; 76:1048-9.
View in: PubMed

Wen PY, Lampson MA, Lampson LA. Effects of gamma-interferon on major histocompatibility complex antigen expression and lymphocytic infiltration in the 9L gliosarcoma brain tumor model: implications for strategies of immunotherapy. J Neuroimmunol. 1992 Jan; 36(1):57-68.
View in: PubMed

Cancer Neurology. 1992.
View in: PubMed

Loeffler JS, Alexander E, Wen PY, Kooy HM, Fine HA, Black PM. Radiosurgery for brain metastases: 5 year experience at the Brigham and Women's Hospital. Lunsford LD, editor. Stereotactic Radiosurgery Update. 1992; 383-392.
View in: PubMed

Loeffler JS, Macklis RM, Wen PY, Fine HA, Alexander E, Coleman CN. Alternative and future strategies in the treatment of malignant gliomas. Sem Rad Oncol. 1992; 36:57-68.
View in: PubMed

Coleman CN, Noll L, Riese N, Buswell L, Howes AE, Loeffler JS, Alexander E, Wen P, Harris JR, Kramer RA, et al. Final report of the phase I trial of continuous infusion etanidazole (SR 2508): a Radiation Therapy Oncology Group study. Int J Radiat Oncol Biol Phys. 1992; 22(3):577-80.
View in: PubMed

Dangond F, Lacomis D, Schwartz RB, Wen PY, Samuels MA. Acute disseminated encephalomyelitis progressing to hemorrhagic encephalitis. Neurology. 1991 Oct; 41(10):1697-8.
View in: PubMed

Schiff D, Wen PY. Parkinson's Disease: Anatomy, Pathology and Therapy (Streifler et al) [book review]. New Engl J Med. 1991; 324:1000.
View in: PubMed

Neurologic complications of cancer therapy. 1991.
View in: PubMed

Loeffler JS, Alexander E, Kooy HM, Wen PY, Fine HA, Black PM. Stereotactic radiosurgery for brain metastases. DeVita VT, Hellman S, Rosenberg SA, editors. Cancer Principles and Practice of Oncology Updates. 1991; 5(2):1-12.
View in: PubMed

Management of Brain Tumors. 1991.
View in: PubMed

Wen P. Brain Tumors. Carskadon M, Rechtschaffen A, Richardson G, Roth G, Siegel J, editors. Encycolpedia of Sleep and Dreaming. 1991.
View in: PubMed

Loeffler JS, Alexander E, Wen PY, Shea WM, Coleman CN, Kooy HM, Fine HA, Nedzi LA, Silver B, Riese NE, et al. Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma. J Natl Cancer Inst. 1990 Dec 19; 82(24):1918-21.
View in: PubMed

Loeffler JS, Alexander E, Hochberg FH, Wen PY, Morris JH, Schoene WC, Siddon RL, Morse RH, Black PM. Clinical patterns of failure following stereotactic interstitial irradiation for malignant gliomas. Int J Radiat Oncol Biol Phys. 1990 Dec; 19(6):1455-62.
View in: PubMed

Kassis AI, Van den Abbeele AD, Wen PY, Baranowska-Kortylewicz J, Aaronson RA, DeSisto WC, Lampson LA, Black PM, Adelstein SJ. Specific uptake of the auger electron-emitting thymidine analogue 5-[123I/125I]iodo-2'-deoxyuridine in rat brain tumors: diagnostic and therapeutic implications in humans. Cancer Res. 1990 Aug 15; 50(16):5199-203.
View in: PubMed

Wen P, Loeffler JS, Morris JH, Lampson LA. The effects of irradiation on major histocompatibility complex expression and lymphocytic infiltration in the normal rat brain and the 9L gliosarcoma brain tumor model. J Neuroimmunol. 1990 May; 27(2-3):239-44.
View in: PubMed

Loeffler JS, Siddon RL, Wen PY, Nedzi LA, Alexander E. Stereotactic radiosurgery of the brain using a standard linear accelerator: a study of early and late effects. Radiother Oncol. 1990 Apr; 17(4):311-21.
View in: PubMed

Loeffler JS, Kooy HM, Wen PY, Fine HA, Cheng CW, Mannarino EG, Tsai JS, Alexander E. The treatment of recurrent brain metastases with stereotactic radiosurgery. J Clin Oncol. 1990 Apr; 8(4):576-82.
View in: PubMed

Wen P, Loeffler JS, Morris JM, Lampson LA. The effect of radiation on leukocytic infiltration and MHC expression in the rat brain and the 9L gliosarcoma brain tumor model. J. Neuroimmunology. 1990; 27:239-244.
View in: PubMed

Antonucci TK, Wen P, Rutter WJ. Eukaryotic promoters drive gene expression in Escherichia coli. J Biol Chem. 1989 Oct 25; 264(30):17656-9.
View in: PubMed

Wen P. Interferon therapy for recurrent gliomas. J Neurosurg. 1989 Apr; 70(4):660-1.
View in: PubMed

Wen P. Interferon Therapy for Malignant Gliomas [letter]. J. Neurosurg. 1989; 70:660.
View in: PubMed

Wen P. Nifedipine for Epilepsy? [letter]. British Medical Journal. 1988; 296:1069.
View in: PubMed

Wen HL, Ho WK, Wen PY. Comparison of the effectiveness of different opioid peptides in suppressing heroin withdrawal. Eur J Pharmacol. 1984 Apr 20; 100(2):155-62.
View in: PubMed

Gibb WRG, Wen P . Current practice of Diagnostic Lumbar Puncture. British Medical Journal. 1984; 289:530.
View in: PubMed

Wen P. [letter]. British Medical Journal. 1984; 287:1983.
View in: PubMed

Top